

NBER WORKING PAPER SERIES

PATENT TROLLS: EVIDENCE FROM TARGETED FIRMS

Lauren Cohen
Umit Gurun
Scott Duke Kominers

Working Paper 20322
<http://www.nber.org/papers/w20322>

NATIONAL BUREAU OF ECONOMIC RESEARCH
1050 Massachusetts Avenue
Cambridge, MA 02138
July 2014

We greatly appreciate the helpful comments of David Abrams, Ufuk Akcigit, David Autor, Pierre Azoulay, James Bessen, Nick Bloom, Daniel Bradley, Eric Budish, Pierre-André Chiappori, Colleen Chien, Wesley Cohen, Chris Cotropia, Sidney Dickstein, Maryann Feldman, Noah Feldman, Robin Feldman, Ken Felter, Amy Finkelstein, Drew Fudenberg, Alberto Galasso, Bernhard Ganglmair, Joshua Gans, Mariassunta Giannetti, Wally Gilbert, Daniel Gottlieb, John Golden, Stuart Graham, Mark Greenstein, Oliver Hart, Cam Harvey, Paul Po-Hsuan Hsu, John Eric Humphries, Bob Hunt, Sonia Jaffe, Louis Kaplow, Jay Kesan, Julian Kolev, Ellen Dickstein Kominers, Paul Kominers, William Kominers, Mark Lemley, Josh Lerner, Stan Liebowitz, Chris Malloy, Alan Marco, Michael Meurer, Shawn Miller, Adair Morse, Petra Moser, Kevin Murphy, Marina Niessner, Jillian Popadak, Jim Poterba, Arti Rai, David Robinson, Assaf Romm, Fiona Scott Morton, David Schwartz, Victoria Schwartz, Amit Seru, Andrei Shleifer, Ted Sichelman, Kathy Spier, Scott Stern, Lars Stole, Balazs Szentes, Alex Teytelboym, Bob Topel, Catherine Tucker, Saurabh Vishnubhakat, Annette Vissing-Jorgensen, Martin Watzinger, Heidi Williams, and seminar participants at the 2015 American Finance Association Meeting, the 2014 Brandeis Entrepreneurship Conference, the 2014 Berkeley CELS Conference, the 2015 Harvard/MIT/INET/CIGI Workshop on Innovation, the 2015 Lund University Conference on Entrepreneurship and Finance, the 2014 NBER Summer Institute Workshop on Innovation, the 2015 NBER Law and Economics Meeting, the 2014 Red Rock Finance Conference, the 2015 Works in Progress Intellectual Property Colloquium (WIPIP), Bentley, Brandeis, Chicago Booth, DePaul, Duke, Harvard, HKU, HKUST, MIT, Nanyang Technological University, Ozyegin University, the Society of Fellows, Texas Christian University, the University of Texas at Dallas, and the USPTO. We are grateful to Daniel McCurdy, Christopher Reohr, and Shashank Tiwari of RPX Corporation for graciously providing data used in this study. We also thank Mike Lloyd and Doris Spielthener of Ambercite for generously providing data. The authors gratefully acknowledge funding from the National Science Foundation (grants CCF-1216095, SciSIP-1535813, and SES-f0847395; 1459912g). Kominers also gratefully acknowledges the hospitality of Microsoft Research New England and the support of the Harvard Milton Fund and the Wu Fund for Big Data Analysis. The views expressed herein are those of the authors and do not necessarily reflect the views of the National Bureau of Economic Research.

NBER working papers are circulated for discussion and comment purposes. They have not been peer-reviewed or been subject to the review by the NBER Board of Directors that accompanies official NBER publications.

© 2014 by Lauren Cohen, Umit Gurun, and Scott Duke Kominers. All rights reserved. Short sections of text, not to exceed two paragraphs, may be quoted without explicit permission provided that full credit, including © notice, is given to the source.

Patent Trolls: Evidence from Targeted Firms
Lauren Cohen, Umit Gurun, and Scott Duke Kominers
NBER Working Paper No. 20322
August 2014, Revised April 2016
JEL No. D2,K1,O31

ABSTRACT

We develop a theoretical model of, and provide the first large-sample evidence on, the behavior and impact of non-practicing entities (NPEs) in the intellectual property space. Our model shows that NPE litigation can reduce infringement and support small inventors. However, the model also shows that as NPEs become effective at bringing frivolous lawsuits, the resulting defense costs inefficiently crowd out some firms that, absent NPEs, would produce welfare-enhancing innovations without engaging in infringement. Our empirical analysis shows that on average, NPEs appear to behave as opportunistic patent trolls. NPEs sue cash-rich firms—a one standard deviation increase in cash holdings roughly doubles a firm's chance of being targeted by NPE litigation. We find moreover that NPEs target cash unrelated to the alleged infringement at essentially the same frequency as they target cash related to the alleged infringement. By contrast, cash is neither a key driver of intellectual property lawsuits by practicing entities (e.g., IBM and Intel), nor of any other type of litigation against firms. We find further suggestive evidence of NPE opportunism, such as forum shopping and targeting of firms that may have reduced ability to defend themselves against litigation. We find that NPE litigation has a real negative impact on innovation at targeted firms: firms substantially reduce their innovative activity after settling with NPEs (or losing to them in court). Moreover, we neither find any markers of significant NPE pass-through to end innovators, nor of a positive impact of NPEs on innovation in the industries in which they are most prevalent.

Lauren Cohen
Harvard Business School
Baker Library 273
Soldiers Field
Boston, MA 02163
and NBER
lcohen@hbs.edu

Scott Duke Kominers
Society of Fellows
Harvard University
Soldiers Field
Boston, MA 02163
kominers@fas.harvard.edu

Umit Gurun
University of Texas at Dallas
School of Management
800 W Campbell Rd. SM41
75080 Richardson, TX
umit.gurun@utdallas.edu

Clearly defined property rights are essential for well-functioning markets. In the case of intellectual property (IP), however, property rights are complex to define, because unlike ownership of physical assets, the space of ideas is difficult to delineate. The United States and many other countries protect inventors' IP through *patents*, property rights allowing ideas' owners sole rights of commercialization—equivalently, the right to block commercialization of arguably similar inventions—for a period of time. In the United States, the legal system is the arbiter of patent infringement; hence, legal action (or the threat of legal action) is the main lever by which patent holders challenge alleged intellectual property infringers.

A new organizational form, the *non-practicing entity* (hereafter, *NPE*), has recently emerged as a major driver of patent litigation. NPEs amass patents not for the sake of producing commercial products, but in order to claim license fees and/or litigate infringement on their patent portfolios. The rise of NPEs has sparked a debate regarding NPEs' value and impact on innovation: Proponents of NPEs argue that NPEs serve a key financial intermediary role, policing infringement by well-funded firms that could otherwise infringe upon small inventors' IP at will. Opponents cast NPEs as organizations that simply raise the costs of innovation by exploiting the fact that an imperfect legal system will rule in their favor sufficiently often—even if no infringement has actually occurred—that the credible threat of the legal process can yield rents from producing, innovative firms.¹ In part reflecting the debate on NPEs, there have been (as of today) a dozen bills introduced in Congress proposing to regulate the licensing and assertion of patents.²

In this paper, we provide the first large-sample evidence on precisely which corporations

¹Bessen and Meurer (2014) estimate that from 2007 to 2010, litigation (and settlement) losses due to NPEs averaged over \$83 billion per year in 2010 dollars (just summing over the losses to publicly traded firms). In magnitude, this corresponds to over 25% of annual United States industrial R&D investment.

²In the last four years, Congress has considered the Innovation Act (H.R. 9 and H.R. 3309), the Targeting Rogue and Opaque Letters (TROL) Act (H.R. 2045), the Patent Transparency and Improvements Act (S. 1720), the Patent Quality Improvement Act (S. 866), the Patent Abuse Reduction Act (S. 1013), the Patent Litigation Integrity Act (S. 1612), the Innovation Protection Act (H.R. 3309), the Patent Litigation and Innovation Act (H.R. 2639), the Saving High-tech Innovators from Egregious Legal Disputes (SHIELD) Act (H.R. 845), the Stopping the Offensive Use of Patents (STOP) Act (H.R. 2766), and the End Anonymous Patents Act (H.R. 2024). Meanwhile, the United States Patent and Trademark Office (2015) has undertaken an initiative on “Enhancing Patent Quality.”

NPEs target in litigation, when NPE litigation occurs, and how NPE litigation impacts targeted firms' innovative activity.

We begin with a parsimonious model of an innovative economy in which a large firm must decide whether to innovate, and—conditional on innovating—must also decide whether to reduce the costs of innovation by infringing upon a small inventor's IP. NPEs help small inventors litigate in response to infringement by the large firm, but can also sometimes win lawsuits when no infringement has occurred.

Our theoretical model supports both sides of the NPE debate: NPE litigation can both reduce infringement and promote a transfer to inventors when infringement occurs, although the value of NPEs to inventors—both in terms of license fees and receipts through litigation—is only as large as the fraction of the damage award that NPEs pass through. As NPEs become effective at bringing frivolous lawsuits, however, the resulting defense costs inefficiently crowd out some firms that, absent NPEs, would prefer to engage in innovation without infringing. Somewhat paradoxically, we also find that the possibility of frivolous lawsuits can lead some innovating firms to infringe *more* because avoiding infringement may not deter suit.

The theory illustrates that the key question for assessing NPEs' welfare impact concerns lawsuit targeting behavior: *Do NPEs on average police against true infringement, or do they primarily behave opportunistically, bringing lawsuits irrespective of whether infringement has occurred?* It is impossible for us to measure targeted firms' infringement activity directly, especially given that most NPE lawsuits are settled before even early stages of evidence discovery occur. However, we can—and do—look for empirical evidence of opportunistic behavior.

We work with two independent sources of data on NPE litigation activity: proprietary data from RPX Corporation and hand-coded, finely classified data assembled by Cotropia, Kesan, and Schwartz (2014). Together, these data sources cover the complete universe of NPE litigation from 2005 to 2015. We combine our data on NPEs with external data on publicly traded firms.

Using our linked data, we show that NPEs appear to behave opportunistically: they target firms that are flush with cash (controlling for all other characteristics) and firms that have had recent, positive cash shocks. NPEs even target firms that earn their profits from business segments having nothing to do with the allegedly infringing segments. Our findings suggest, for example, that an NPE would likely sue a firm regarding alleged information technology infringement even if the firm is earning all its revenue from a lumber division entirely unrelated to the information technology division—and even if the information technology division is unprofitable. Indeed, a one standard-deviation increase in cash level increases the probability of being sued by an NPE by 7.40% ($t = 4.25$)—a twofold increase, and profitability in unrelated business segments is almost as predictive of NPE litigation as is profitability in the segment related to the alleged infringement.

Meanwhile, we find some evidence that NPEs may not be policing infringement. The cash-targeting we observe is mostly the behavior of large “patent aggregator” firms; small inventors’ lawsuits show a different targeting pattern, in which defendants’ cash holdings are not a significant factor. There is also evidence that NPEs bring lower-quality lawsuits, and some evidence that NPEs are actively forum shopping.

In theory, our finding that cash/profitability is a first-order determinant of NPE litigation could simply be picking up a general characteristic of IP litigation, or of litigation more generally. However, our results show otherwise: *Practicing entities* (*PEs*), such as IBM and Intel, who also sue each other for patent infringement, do not behave in the same way as NPEs. We hand-collected the universe of patent infringement cases brought by PEs against PEs in our sample period, and find that, if anything, PEs are slightly *less* likely to sue firms with high cash balances.³ Similarly, we found that cash is not a significant determinant of other (non-IP) forms of litigation—tort, contract, securities, environmental, or labor. This comparison suggests that our results on NPE litigation behavior do not just reflect general

³All of the other key determinants of NPE targeting have (statistically and economically) no impact on PE litigation behavior, with the exception of ongoing, non-IP-related cases, which has a positive impact on targeting for NPEs, but a negative impact for PEs.

characteristics of litigation. Rather, our findings are consistent with agent-specific motivations for NPEs in targeting firms flush with cash.

Using several different empirical measures, we also find that NPEs target firms against which they have a higher *ex ante* likelihood of winning. First, we show that NPEs are significantly more likely to target firms that are busy dealing with other, non-IP-related litigation. Being tied up with outside litigation increases the probability of being sued by an NPE by roughly 19% ($t = 2.38$). Moreover, we show that, controlling for all other characteristics, firms with smaller legal teams have a significantly higher probability of being targeted by NPEs.

Lastly, we examine the real impacts of NPE litigation on targeted firms' innovative activity. Using a differences-in-differences approach, we find that firms that lose to NPEs (either in court or through settlement) reduce their research and development investment by roughly 20% going forward, relative to *ex ante* identical firms.⁴ Thus, our evidence suggests that NPE litigation causes a real decrease in innovation at targeted firms. Of course, when NPEs win lawsuits, some of the losses to the targeted PE—part of the settlement or damage award, but not the legal costs—should eventually flow back to end inventors. The best available estimates suggest, however, that only a small fraction of the damages won by NPEs are actually paid back to innovators (Bessen, Ford, and Meurer (2011); Bessen and Meurer (2014)). As part of our theoretical model illustrates, when only small transfers reach end inventors, NPEs' value in encouraging invention directly is significantly dampened.

Taken as a whole, our evidence appears most consistent with the view that NPEs on average behave as patent trolls. NPEs chase cash, and have a real negative impact on targeted firms' innovative activity. Alternative interpretations simply do not seem to explain the entire body of evidence. For instance, our results on cash-targeting might be consistent with the possibility that targeted firms are knowingly infringing and are stockpiling cash in anticipation of litigation; however, this alternate explanation is at odds with our finding that

⁴To control for selection of firms targeted by NPEs, we compare firms that are sued by NPEs and “win” to those are sued by NPEs and “lose.”

NPEs are especially likely to target firms that have had cash shocks, and/or are embroiled in non-IP-related lawsuits. Meanwhile, the idea that NPEs solely target firms that profitability infringe on NPEs' intellectual property is inconsistent with our finding that profitability in related and unrelated operating segments are almost equally predictive of suit.

The remainder of the paper is organized as follows. Section 1 provides background and a literature review. Section 2 develops our model of the economics of innovation and intellectual property litigation. Section 3 describes our data sources. Section 4 presents our empirical results on NPE targeting. Section 5 shows evidence on the real impacts of NPE litigation behavior on innovation. Section 6 provides a discussion, and Section 7 concludes.

1 Background

A United States inventor's patenting process begins with an application to the United States Patent and Trademark Office (USPTO), which assigns the application to a patent examiner. The examiner's job is to compare the filed patent's claims to prior art, in order to determine whether the claimed invention is novel and nonobvious.⁵ If the examiner decides to grant the claims in an application, then the USPTO issues a patent to the applicant.⁶ The patentability of a patent's claims can be challenged in administrative proceedings before USPTO. Patent validity can be challenged in one of the 94 federal district courts by presenting prior art that may have been overlooked by USPTO examiners.

Since a patent confers the right to exclude others from "practicing" an invention, patent owners can sue anyone who uses, makes, sells, offers to sell, or imports their inventions without legal permission. If a patent infringement lawsuit is not dismissed in its initial stages, it proceeds to the *discovery* phase, in which both the accused infringer (defendant) and the patent owner (plaintiff) supply documents intended to demonstrate how the allegedly

⁵*Prior art* refers to other patents, publications, and publicly disclosed but unpatented inventions that predate the patent application's filing date.

⁶In 2013, the average time between application and initial examiner report was 18.2 months and, on average, it took 29.1 months for the USPTO to issue a patent. The USPTO granted 302,948 patents in 2013. For other USPTO-related statistics, see <http://www.uspto.gov/about/stats/>.

infringing product is made. If a party does not make or sell products or provide services based on the patented invention, then it is likely to have far fewer documents to disclose. Consequently, as NPEs do not produce products, the discovery phase can be far less costly for NPE plaintiffs than for defendants.

If an infringement suit is not settled during the discovery phase, then a court interprets the parties' claims, making determinations both as to whether the patent is valid and whether infringement occurred. A judge or jury who rules in favor of the patent owner can award monetary damages and/or issue an injunction to prohibit further infringement.

The amount of patent-related litigation has increased threefold since 2005 (see Figure 1). According to a recent United States Government Accountability Office (2013) report, three factors contributed to the rise in IP litigation: (1) the number of patents (especially software-related patents) with unclear scope has increased; (2) courts have been granting large monetary awards in infringement lawsuits, even for ideas that make only small contributions to a product; and (3) markets place a larger valuation on patents than they did before.

Large-scale NPE patent litigation is a recent development; consequently, the empirical literature on NPEs is limited, but growing rapidly. Our paper contributes to this literature by providing the first large-sample evidence about which public corporations NPEs choose to litigate, when NPEs target those companies, and how NPE litigation impacts innovative activity at targeted firms.

Many of the existing empirical studies on NPEs have found results consistent with those we present: In a series of surveys, Chien (2013a) found evidence of cash-targeting by NPEs, consistent with the empirical results we show in Section 4.1. Leychkis (2007) has found evidence that NPEs frequently forum shop (see Section 4.6). Meanwhile, economists and legal scholars have estimated both (1) high direct costs of NPE litigation, suggesting significant harm to targeted firms (Chien (2014); Feldman (2014); Bessen and Meurer (2014)), and (2) low rates of pass-through of NPE winnings to end inventors suggesting little direct value of NPEs to small inventors (Bessen, Ford, and Meurer (2011)). Recent work sought to measure

the indirect costs of NPE litigation, as well, finding that NPE litigation substantially reduces innovation at targeted firms (Chien (2013a); Tucker (2014); Smeets (2015)) and makes it harder for targets to acquire venture capital funding (Kiebzak, Rafert, and Tucker (2016)). Cotropia, Kesan, and Schwartz (2014) developed a detailed, hand-coded dataset of 2010 and 2012 NPE litigation activities; we use this data to confirm our results out-of-sample (see Section 4.9.1). Scott Morton and Shapiro (2014) provided both theoretical and empirical evidence that—given the costs and deadweight losses of NPE litigation—the positive spillovers from NPEs would have to be “very substantial” in order to justify NPE litigation from a social welfare perspective.^{7,8}

While there is some evidence that patent aggregation and litigation may have been socially valuable prior to 2000 (Galasso, Schankerman, and Serrano (2013); see also Galasso and Schankerman (2010)), survey evidence suggests that in recent years, patent assertion activity may have done little to promote innovation (Feldman and Lemley (2015)).⁹ A concurrent literature in economics suggests that the impact of patent rights on innovation is highly heterogeneous (Galasso, Schankerman, et al. (2015)); in particular, patents may discourage valuable follow-on innovation (Williams (2013); see also Sakakibara and Branstetter (2001); Lerner (2009); Williams (2015)).¹⁰ Consequently, the law and policy literatures have begun to sort out potential deficiencies in the patent system more broadly (see, e.g., Lemley and Melamed (2013); Budish, Roin, and Williams (2015); United States Patent and Trademark

⁷Shrestha (2010) has argued that NPE litigation behavior is closely analogous to that of PEs, but his empirics are hard to square with our data. The Shrestha (2010) study is based on a subsample of only fifty-one NPEs, hand-selected on the basis that their names appear frequently in newspapers and other media. Shrestha (2010) reports fewer than 100 NPE lawsuits per year between 2000 and 2008 and no rise in the total number of IP lawsuits over the 2000-2008 period—inconsistent with both our findings and those of Cotropia, Kesan, and Schwartz (2014).

⁸In parallel, a growing theory literature has begun to illustrate how uncertainty regarding patent quality and/or technology overlap may lead to patent trolling behavior (Lemley and Shapiro (2005); Bessen and Meurer (2006); Choi and Gerlach (2014)).

⁹Feldman and Lemley (2015) find that “very few patent licenses from assertion actually lead to new innovation; most are simply about paying for the freedom to keep doing what the licensee was already doing,” both in the case of NPE licensing/litigation *and* in the case of PE licensing/litigation.

¹⁰Using data obtained from an NPE (but not studying NPEs, *per se*), Abrams, Akcigit, and Popadak (2013) found an inverted-U relationship between patent citations and patent value (as measured in terms of associated revenue).

Office (2015)), while proposing potential reforms (Lemley and Shapiro (2006); Schwartz and Kesan (2014); see especially the work of Helmers, Love, and McDonagh (2013), which hints at how policy lessons from the United Kingdom could be used to reduce patent trolling in the United States).

Our work is also related to the literature that examines the choice between settlement and the pursuit of a court decision. Spier (2005) provides an excellent review of the economics of litigation.¹¹ While we focus solely on intellectual property, our paper is also related to the well-developed literature on the effect of litigation risk on firm activities.¹²

2 Model

We now introduce a model of innovation and litigation: A firm decides whether to invest in *innovation*, which has net benefit $v > 0$. If the firm does not innovate, then it produces a “safe” product which returns 0. If the firm does innovate, then it must choose whether to *infringe* on the intellectual property of a small inventor; infringement reduces the costs of innovation by $\pi > 0$ (so that innovation with infringement yields net benefit $v + \pi$).

If innovation occurs, then the inventor can bring a suit against the firm at cost c_i ; in that case, the firm pays court costs c_f .¹³ The inventor can bring a suit (i) on his own or (ii) indirectly through an NPE. For now, we assume that there is no possibility of licensing the inventor’s intellectual property; we later add licensing to the model, and investigate the impacts of NPEs on license rates.

¹¹Previous surveys include those of Cooter and Rubinfeld (1989), Hay and Spier (1998), and Daughety and Reinganum (2000).

¹²Prior research has investigated the impact of litigation risk on several characteristics, including cash holdings (Arena and Julio (2011)), equity-based compensation (Jayaraman and Milbourn (2009)), IPO underpricing (Lowry and Shu (2002); Hanley and Hoberg (2012)), institutional monitoring and board discipline (Cheng, He Huang, Li, and Lobo (2010)), conservatism in debt contracting (Beatty, Weber, and Yu (2008)), audit fees (Seetharaman, Gul, and Lynn (2002)), and auditors’ resignation decisions (Shu (2000)). Papers have also investigated the relationship between managers’ financial reporting and disclosure decisions and firms’ litigation risk (see, e.g., Skinner (1994, 1997); Francis, Philbrick, and Schipper (1994); Johnson, Kasznik, and Nelson (2000); Rogers and Van Buskirk (2009)).

¹³We assume throughout that the NPE passes the costs of litigation through to the inventor. This assumption is not necessary for the qualitative results—it just serves to simplify the exposition.




Figure 1: The innovation and litigation game: In stage 1, the firm decides whether to innovate. If the firm chooses to innovate, then he must decide whether to infringe. Then, the inventor litigates (either on his own or through the NPE) if doing so is profitable. For each end node, the top term denotes the firm's payoff, and the bottom term denotes the inventor's payoff.

Courts are assumed to be imperfect. The likelihood that a suit is successful depends on whether infringement has actually occurred, and on whether an NPE is involved. The probability that a suit succeeds is given by

| | if(infringement) | if(no infringement) |
|----------------------------------|------------------|---------------------|
| the inventor sues on his own | \bar{p}_i | \underline{p}_i |
| the inventor sues through an NPE | \bar{p}_n | \underline{p}_n |

We normalize \underline{p}_i to 0, so that the inventor has no chance of succeeding in court unless infringement has occurred. We also assume that

$$\bar{p}_n > \bar{p}_i \text{ and } \underline{p}_n > \underline{p}_i = 0,$$

i.e., that the NPE is always more effective in bringing suit than the inventor is alone—irrespective of whether infringement has occurred. It is also sensible to assume that $\bar{p}_i > 0$

and $\bar{p}_n > \underline{p}_n$, although these assumptions are not strictly necessary for our analysis.

If the inventor sues on his own, he receives the full damage award δ from the firm. If instead the inventor sues through an NPE, he receives fraction $\lambda < 1$ of the damages δ ; fraction $(1 - \lambda)$ go to the NPE.

If the firm infringes, then the inventor brings suit when

$$\max\{\bar{p}_i\delta - c_i, \lambda\bar{p}_n\delta - c_i\} > 0 \iff \max\{\bar{p}_i, \lambda\bar{p}_n\} > \frac{c_i}{\delta}.$$

When $\bar{p}_i \geq \lambda\bar{p}_n$, the inventor sues on his own; when $\bar{p}_i < \lambda\bar{p}_n$, the inventor sues through the NPE.

Thus, if $\max\{\bar{p}_i, \lambda\bar{p}_n\} < \frac{c_i}{\delta}$ (bringing suit is never profitable for the inventor in case of infringement), then the firm will always choose to innovate and infringe (and the inventor will never sue), so that the firm receives total payoff $v + \pi$ and the inventor receives 0.

If $\max\{\bar{p}_i, \lambda\bar{p}_n\} > \frac{c_i}{\delta}$ and the firm innovates and infringes, then the firm receives total payoff

$$v + \pi - c_f - \bar{p}_*\delta, \tag{1}$$

where here we take

$$\bar{p}_* = \begin{cases} \bar{p}_i & \bar{p}_i \geq \lambda\bar{p}_n \\ \bar{p}_n & \bar{p}_i < \lambda\bar{p}_n. \end{cases}$$

In that case, i receives $(\max\{\bar{p}_i, \lambda\bar{p}_n\})\delta - c_i$.

If the firm does not infringe, then the inventor brings suit (through the NPE) when

$$\lambda\underline{p}_n\delta - c_i > 0 \iff \lambda\underline{p}_n > \frac{c_i}{\delta}.$$

In this case, if the firm innovates, then he receives total payoff

$$v - c_f - \underline{p}_n\delta. \tag{2}$$

We henceforth assume that $\max\{\bar{p}_i, \lambda\bar{p}_n\} > \frac{c_i}{\delta}$, so that bringing suit is profitable for the inventor only if the firm infringes. If $\lambda\underline{p}_n < \frac{c_i}{\delta}$, then no suit occurs unless the firm infringes, so if the firm innovates, then he infringes exactly when the benefits of infringement outweigh the costs, i.e., when

$$v + \pi - c_f - \bar{p}_* \delta > 0 \quad \iff \quad v + \pi > c_f + \bar{p}_* \delta.$$

If $\lambda\underline{p}_n > \frac{c_i}{\delta}$, so that bringing suit is profitable for the inventor even if the firm does not infringe, then, conditional on choosing to innovate, the firm's decision as to whether to infringe depends on the comparison of (1) and (2). If the firm innovates, then he infringes exactly when

$$v + \pi - c_f - \bar{p}_* \delta > v - c_f - \underline{p}_n \delta \quad \iff \quad \frac{\pi}{\delta} > \bar{p}_* - \underline{p}_n. \quad (3)$$

2.1 Impact of NPEs on Innovation and Infringement

Combining the preceding observations, we see that:

- When the NPE is significantly more effective at bringing suit than the individual inventor is (i.e., when $\bar{p}_n > \bar{p}_i/\lambda$), and $\underline{p}_n \rightarrow 0$, so that the NPE is ineffective at bringing *nuisance suits* (that is, suits when no infringement has occurred), the NPE reduces total infringement: A suit occurs only after infringement, and the firm infringes if and only if

$$v + \pi > c_f + \bar{p}_n \delta. \quad (4)$$

Importantly, infringement is strictly lower than if the NPE were absent, as (4) is tighter than $v + \pi > c_f + \bar{p}_i \delta$, which is the condition that determines infringement absent the NPE.

- However, as the NPE becomes better at bringing nuisance suits, that is, as $\underline{p}_n \rightarrow 1$, we have $(\bar{p}_* - \underline{p}_n) \rightarrow 0$, so that (3) always holds. In that case, all innovating firms will

infringe—even if the benefits of infringement are small. Consequently, if either the defense costs c_f or the damages δ are sufficiently large, then we have

$$v + \pi - c_f - \bar{p}_* \delta < 0,$$

so that the firm will choose not to innovate.

- If $\lambda\delta > c_i$ —bringing suit through the NPE is individually rational for the inventor if it is guaranteed to be successful—and either the defense costs c_f or the damages δ are sufficiently large, then as $\underline{p}_n \rightarrow \bar{p}_n \rightarrow 1$, the firm always chooses not to innovate even if, absent the NPE, the firm would choose to innovate without infringing.

Specifically, the firm chooses not to innovate when $v + \pi - c_f - \bar{p}_* \delta < 0$. If $v + \pi - c_f - \bar{p}_i \delta < v$, then the firm would innovate without infringing if there were no chance of nuisance suit. Thus, if \underline{p}_n is sufficiently high and the benefits of infringement are low ($\pi < c_f + \bar{p}_i \delta$), the presence of the NPE leads mid-range innovations (those having values $v < c_f + \bar{p}_* \delta - \pi$) to be crowded out of the market.

2.2 Impact of NPEs on IP Licensing

Now, we suppose that the inventor and firm can agree to license terms *ex ante*, in exchange for committing not to litigate infringement. We assume that the firm has all the bargaining power, so that it can force the inventor to take a license that just barely makes him indifferent regarding litigation.

If the firm innovates and infringes, then the inventor stands to earn

$$\max\{\bar{p}_i \delta - c_i, \lambda \bar{p}_n \delta - c_i\} > 0$$

if he brings a lawsuit. Thus, the firm can license the invention for

$$\max\{\bar{p}_i\delta - c_i, \lambda\bar{p}_n\delta - c_i\}. \quad (5)$$

Examining (5), we see that as expected, the NPE only improves the terms of licensing for the inventor when $\bar{p}_i < \lambda\bar{p}_n$, that is, when the inventor would prefer to sue through the NPE instead of litigating on his own. But then the value of the license to the inventor is mediated by the rate at which the NPE passes value through to the inventor: No inventor gains more through licensing than he would earn through bringing suit (although licensing is more efficient because it saves court costs). In particular, if λ is small, then the inventor does not gain much through licensing.¹⁴

2.3 Welfare Impact of NPEs

Our model illustrates that the welfare impact of NPEs is ambiguous.

When NPEs are more effective at bringing suit than individual inventors are, the threat of NPE litigation can reduce infringement and promote a transfer to inventors when infringement occurs. However, the value of NPEs to inventors is mediated by the fraction λ of the damage award that NPEs pass through: for the NPE to be a useful intermediary, it is necessary that $\bar{p}_n > \bar{p}_i/\lambda$ —either most of the proceeds of the suit must go to the inventor, or the NPE must be *much* more effective at litigation than the inventor is. The possibility of NPE-backed lawsuits may help inventors extract licensing fees from firms, but again this effect is mediated by the pass-through rate λ ; if λ is small, then the inventor cannot extract a high licensing fee.

Meanwhile, if the NPEs become effective at bringing nuisance lawsuits, then in equilibrium NPEs bring lawsuits even absent infringement. Somewhat paradoxically, this leads innovating firms to infringe *more*, since they know that avoiding infringement will not deter suit.¹⁵

¹⁴Even so, when λ is very small, it could still be the case that $\bar{p}_i < \lambda\bar{p}_n$ if, as is commonly believed, small inventors are virtually powerless to bring suits against large firms.

¹⁵This finding echoes the classical insight of Polinsky and Shavell (1989) that when court error is possible, if plaintiffs' costs are low (or if the gains from suit are sufficiently high), then potential defendants will choose

Additionally, the cost of nuisance lawsuits inefficiently crowds out welfare-increasing innovation by some firms that, absent NPEs, would prefer to innovate without infringing.

3 Data

We obtain information on NPEs from RPX Corporation, a company that tabulates information on NPE behavior, including data on patent litigation.¹⁶ RPX Corporation has collected data going back to 1977, capturing from Public Access to Court Electronic Records (PACER) every lawsuit filed by more than 4000 NPEs (approximately 850 parent companies, and 3300 affiliates); the data is thus systematic, and not based on self-reporting.^{17,18} We replicate all of our analysis—and find nearly identical results in magnitude and significance—using the hand-coded, publicly available NPE activity data collected by Cotropia, Kesan, and Schwartz (2014) for the years 2010 and 2012 (see Section 4.9.1 and Appendix Table A4).

Patent assertions by NPEs (e.g., “demand letters”), while not formal legal actions, do occur. Patent assertions are unreported by nature, so there is unfortunately no comprehensive dataset of these actions. However, it is widely believed that informal patent assertions have been in decline recently, and are projected to decline further. The two biggest factors driving this decline are the decreasing credibility of patent assertions (given the availability of the formal legal channel),¹⁹ and the rise of legislation (both state and federal) to hold entities liable for unsubstantiated demand letters.²⁰ Furthermore, as many more NPEs are now suing (see Table I, Panel B), non-legally binding letters simply alleging infringement (and asking to disobey the law, as they will be sued irrespective of whether they obey the law.

¹⁶RPX Corporation defines an NPE as “A firm that derives the majority of its revenue from licensing and enforcement of patents.” Under this definition, traditional legal entities established to license and enforce patents comprise the majority of NPEs. Additionally, individual inventors may be counted, while universities will not be counted (unless they have patent enforcement subsidiaries).

¹⁷Chien (2013b) compared a subsample of about 1000 of RPX’s codings to her own hand-codings, finding no more than 7% disagreement.

¹⁸RPX Corporation cleans its raw filing data (for instance, removing some “administrative duplicates” representing the same case, but moved across districts).

¹⁹One company executive relayed to us his reply to NPEs that send demand letters: “If you have a truly viable case you will sue; otherwise don’t waste my time with this letter(!).”

²⁰See, e.g., the Executive Office of the President (2013) report on “Patent Assertion and U.S. Innovation.”

for money) are becoming less credible signals. The equilibrium result is that the economically large alleged IP infringements appear to be addressed through lawsuits (all of which are in our data), and this is becoming increasingly true over time. We thus feel that RPX Corporation’s systematic and exhaustive collection of NPE lawsuit data likely captures the economically important (and increasingly dominant) component of NPE behavior, even though it does not fully capture patent assertions not backed by litigation (see also Feldman and Lemley (2015) for supporting survey evidence). In Table I (Panel A), we present summary statistics on the firms included in our analysis.²¹

According to RPX Corporation, roughly 69% of NPEs’ patents were acquired externally (purchased) by NPEs and their subsidiaries, whereas 19% were originally assigned to NPEs.²² Panel B of Table I shows the time-series of NPE litigation data through our sample period, 2005-2015. The data clearly indicates that there has been a sharp rise in NPE lawsuits over the past decade.

In total, the data provide detailed information on 21,300 litigation actions by NPEs (i.e., where an NPE is the plaintiff) and 19,621 litigation actions by PEs. RPX’s definition of an NPE includes the following organizational forms: (1) *patent asserters*, entities that earn revenue predominantly through asserting patents, (2) *small inventors*, (3) *non-competing entities (NCEs)*, operating companies asserting patents outside their areas of products or services, and (4) *universities (and research institutions)*. In our study, we exclude NCEs and universities, which make up less than 3% of the sample. In the last column of Panel B of Table I, we tabulate the number of observations in a different database, Lex Machina, that also provides patent litigation records. A comparison of cases in the RPX and Lex Machina datasets indicates that there is little difference between the two data sources.²³

We focus on the cases in which the defendant firm is publicly traded, as for these defendants we can obtain rich, detailed characteristic data for which reporting is required by the Securities

²¹Appendix Table A1 presents detailed descriptions of the specific data fields used in our study.

²²The remaining 12% are a blend of originally assigned and acquired patents.

²³In fact, the time series correlation between RPX and Lex Marchina—the final two columns of Table I, Panel B—is 99.95%.

and Exchange Commission. In Figure 1, we graph the number of NPE and PE case dockets in which the at least one of the defendants is a public firm. By 2015, 11.25% of all publicly traded firms were sued by an NPE each year. This rise in IP litigation is also depicted in Figure 1, which first shows the total rise in patent litigation over our sample period, and then separates the rise into the cases brought by NPEs and IP cases brought by PEs. From Figure 1, it is apparent that the rise in overall IP litigation is entirely driven by NPE suits. PEs' IP litigation has remained constant over the sample period. We revisit and examine more systematically the difference in IP litigation behavior between NPEs and PEs in Section 4.2.

We obtain firm-level patent information from the database used by Kogan, Papanikolaou, Seru, and Stoffman (2012).²⁴ This database contains utility patents issued by the USPTO between January 1, 1926 and November 2, 2010, along with citation data on those patents.²⁵ We obtain information on the in-house legal counsels and law firm associations of public firms from ALM Legal Intelligence, which searches public records to find outside counsel used by companies for corporate, contract, labor, tort, and IP litigation.

To identify involvement in litigation events not related to IP, we use the Audit Analytics Litigation database, which covers the period from 2005 to 2013 and reports information on litigation for Russell 1000 firms from legal disclosures filed with the SEC. Audit Analytics collects details related to specific litigation, including the original dates of filing and locations of litigation; information on plaintiffs, defendants, and judges; and, if available, the original claim amounts and the settlement amounts.

²⁴We thank Leonid Kogan, Amit Seru, Noah Stoffman, and Dimitris Papanikolaou for providing both patent and citation data.

²⁵The USPTO defines *utility patents* as patents issued for the invention of new and useful processes, machines, manufactures, or compositions of matter, or new and useful improvements thereof. A utility patent generally permits its owner to exclude others from making, using, or selling the patented invention for a period of up to twenty years from the date of patent application filing. Approximately 90% of the patent documents issued by the USPTO in recent years have been utility patents.

4 Results

4.1 Cash-Targeting

We begin by examining the determinants of NPE litigation behavior. As a start, we parameterize a central concern of opponents to NPEs; namely, that NPEs bring nuisance suits (i.e., $p_n > \frac{c_i}{\delta\lambda}$), and that their prime driver is the ability of targeted firms to pay large damages or settlement fees. We use both levels of cash balances on the balance sheet (*CashLevel*) and changes in cash holdings (*CashShock*) as proxies for the potential proceeds of a suit. We include several firm- and time-level control variables, such as the firm’s market value, book-to-market ratio,²⁶ the prior year’s stock market performance, and the number of recent patents issued to the firm, *R&D*, along with time and firm fixed effects. In Table II, we report OLS regression results of the following specification:

$$SuedByNPE = f(CashLevel, TotalAssets, MVE, BM, R\&D, PastReturn, PatentStock, CashShock).$$

The outcome variable, *SuedByNPE*, is a dummy equal to 1 if the firm was litigated by an NPE in a particular year. *CashLevel* is the total amount of cash reported on the balance sheet as of the beginning of the previous fiscal year. *CashShock* is a dummy variable equal to 1 if the change in cash in the past current fiscal year, compared to the previous fiscal year’s cash level, is among the top 95% of cash changes in the firm’s industry cross-section. We include industry or firm fixed effects to capture unobserved industry- or firm-level time-invariant factors that are correlated with NPE targeting. Likewise, we include time fixed effects to control for variation in litigation activity specific to a given year and for any time trends in litigation propensity. We report various specifications to show the incremental value of each covariate on overall model fit. Column 4 of Table II represents our preferred specification, which includes firm-level characteristics (market value, book-to-market ratio, asset size, research and development expense, prior stock performance of equity), time and firm fixed effects,

²⁶We use Tobin’s Q to proxy for investment opportunities.

and our cash variables. We use a log transformation of all variables to minimize the effect of outliers.²⁷ We cluster our standard errors at the firm level in order to broadly allow for any time-series dependency in the probability of being sued over the course of the sample period.

Table II uncovers a strong and consistent pattern: Firms with large cash balances and firms with positive shocks to their cash holdings are more likely to be targeted by NPEs. Controlling for other determinants and for firm and time fixed effects, the *CashLevel* coefficient in Column 4, is 0.0565 ($t = 4.25$), is large and significant, as is the *CashShock* coefficient, 0.0167 ($t = 2.06$). To get an idea of the magnitudes, we use the coefficient estimates in the full specification in Column 4. With the average firm-level cash holding of \$579 million, the 0.0565 coefficient on *CashLevel* implies that a one standard-deviation increase in cash balance increases the chances of being sued by 7.40%. Given that the unconditional probability of being sued for patent infringement is approximately 8.60%, this is nearly a twofold higher probability of being targeted (16.00% vs. 8.60%). This estimate shows the large economic impact of cash on NPE targeting.

In sum, Table II reveals the strong impact of cash on NPEs' targeting decisions. In particular, in Column 4, both of these effects are estimated including firm and time fixed effects, along with fine controls for firm size, past returns, R&D spending, and patent stock. Thus, the large coefficients can be interpreted as showing that a firm is likely to be targeted by NPEs when it has an abnormally high cash level (or a shock to that cash level) relative to all other firms' cash levels (and shocks).

We have run a number of robustness checks exploring the relationship between cash and NPE litigation. First, in Panel B of Table VIII, we consider specifications identical to those of Table II, but using logit and probit estimation as opposed to OLS. The coefficients on cash remain large and significant, with the implied magnitudes even slightly larger in point estimate. Furthermore, we replace the dummy dependent variable *SuedByNPE* with its continuous counterpart *TimesSued*, measuring the number of times a given firm is sued

²⁷Neither the magnitudes nor the significance levels of our coefficients change appreciably when we do not use log transformation.

by NPEs in any given year. We estimate the model in OLS (and Tobit) in the table, and find that both *CashLevel* and *CashShock* are large and significant predictors of the intensity with which firms are sued by NPEs. Next, in Appendix Table A3, we test for any impact of multicollinearity on the estimates. From Appendix Table A3, we see that multicollinearity is clearly not an issue. The coefficients on *CashLevel* and *CashShock* remain large, significant, and—importantly—stable irrespective of the addition or deletion of any given control variable.²⁸ Lastly, we cluster standard errors by year (instead of by firm), and estimate specifications with industry (as opposed to firm) fixed effects in Appendix Table A3. Both of these adjustments have nearly no impact on the magnitude or significance on the *CashLevel* and *CashShock* coefficients.

4.2 IP Litigation Behavior of Practicing Entities (PEs) & Litigation Behavior against Firms more Generally

A reasonable response to the results in Table II is to expect that cash-targeting should be the behavior of *any* profit-maximizing litigant. It makes little sense to sue a firm—incurring potentially sizable legal costs, along with the opportunity costs of foregone suits—if the target firm has no *ex ante* ability to pay. However, as it turns out, cash targeting is *not* generally a first-order determinant of litigation outside NPE IP lawsuits. To see this, we compare the determinants of NPE IP litigation to those of PE IP litigation, and to the determinants of litigation activity more broadly.

4.2.1 IP Lawsuits Brought by PEs

NPEs do not have a monopoly on Intellectual Property litigation. PEs like Apple, General Electric, and Intel also sue each other for patent infringement. If our results were simply picking up general characteristics of IP litigation, then we might expect to see PEs behaving in much the same way as NPEs. In order to compare PE and NPE behavior, we hand-collected

²⁸The coefficients are essentially unchanged in magnitude and significance across specifications.

the universe of patent infringement cases brought by PEs against other PEs in the same period. As we already observed in Figure 1, the rise in IP litigation is driven by NPEs. While NPEs have an exponential-type rise in IP litigation over the sample period, PEs' IP litigation has remained essentially constant. Thus, in an aggregate time-series sense, we see a difference between the litigation behavior of the two groups.

We run a more formal analysis of the determinants of PE lawsuits, using a set-up identical to that used for NPEs in Section 4.1. We replicate the specifications used in Table II, but this time we use *SuedByPE* as the dependent variable.²⁹ The results of this analysis are in Column 1 of Table III. We see that PEs behave very differently from NPEs. Nearly all of the predictors of NPE litigation behavior have a small and insignificant impact on PE litigation behavior. Moreover, the impact of cash goes mildly in the *opposite* direction (in point estimate).

Of course PEs likely have motivations for IP litigation beyond those of NPEs (e.g., competitive responses, defensive tactics, retaliative litigation). However, this comparison does suggest that the results on NPE litigation behavior do not simply reflect general characteristics of IP litigation over time or within the cross-section. Rather, they are consistent with agent-specific motivations for NPEs in targeting firms flush with cash.

4.2.2 Other Litigation Behavior

We next move on to a more general setting, considering *all* lawsuits filed against publicly traded firms. If the cash-targeting in NPE IP litigation is a general feature of litigation—as we might think—then cash-targeting should show up in other litigation categories. From Audit Analytics, we collected the entire slate of disclosed legal actions taken against publicly traded firms. Audit Analytics covers the 2005–2013 period and reports information on litigation against Russell 1000 firms, recording legal disclosures filed with the SEC.³⁰

²⁹ *SuedByPE* is a dummy variable equal to 1 if a firm faces IP lawsuits from PEs in a given year.

³⁰ Audit Analytics collects details related to specific litigation, including the original dates of filing and locations of litigation; information on plaintiffs, defendants, and judges; and, if available, the original claim and final settlement amounts.

We run specifications identical to those of Table II, for all other litigation categories. The results are shown in Table III. From Column 2 to 5 of Table III, we see that large amounts of cash are not positively related to non-IP litigation actions (tort, contract, securities, environment, and labor).

So what drives non-IP litigation? The results suggest that the main determinant of non-IP cases is the infraction itself (e.g., polluting a local waterway in the case of an environmental suit). Importantly, these other cases often have more concrete and provable actions taken by the defendant, as opposed to IP infringement, in which the property right is itself more amorphously defined (and so infringement is more subjectively determined). This extra scope given in IP cases makes IP a potentially good candidate for opportunistic, purely profit-driven legal activity.

The sum of the evidence in Tables II and III shows that NPE IP litigation is unique in its cash-targeting nature, in comparison to other forms of litigation, and even within the fine space of IP litigation. In the following sections we explore more closely the behavior of NPEs, and examine whether NPE behavior appears to be—on average—opportunistic legal action.

4.3 Targeting Unrelated Profits

In this section we examine whether NPEs go after profits *unrelated* to alleged infringement. Using finely reported business segment-level disclosures, we are able to extract and separate profits in the business segments related to the alleged infringement from those profits in unrelated segments.

As of 1976, all firms are required by Statement of Financial Accounting Standards (SFAS) 14 (Financial reporting for segments of a business enterprise, 1976) and SFAS 131 (Reporting desegregated information about a business enterprise, 1998) to report financial information for any industry segment that accounts for more than 10% of total annual sales. Using these segment-level filings, we extract information on industry classification, sales, and cost of goods sold for each segment of each conglomerate between 2005 and 2015. We then use the

concordance between international patent classification (IPC) codes and four-digit United States Standard Industrial Classifications (SIC) to identify the conglomerates' segments associated with the NPE-litigated patents.³¹

After identifying segments related to allegedly infringed patents, we split each NPE-targeted firm's segments into *related segments* and *unrelated segments*. A firm's related segments are those segments that could potentially use the litigated patent in regular operations; its unrelated segments are those that could not. We compute each segment group's gross profits by subtracting cost of goods sold from segment group sales.³²

We note that not all conglomerates report segment-level information in the same format. For example, a conglomerate may report information on one segment only, or it may report cost of goods sold for only one of the segments in which it operates. Therefore, our final sample contains only conglomerates for which we have both cost and revenue data on at least one related segment and one unrelated segment.

We estimate a model to test whether the probability of being sued by an NPE is correlated with profits obtained from *unrelated* segments, even after controlling for the profitability of related segments. In this model, we include conglomerate fixed effects to control for conglomerate-level unobserved litigation probability. We also control for industry-wide shocks to profitability, by including a variable measuring the average profitability of the segment's industry.

The results of our segment-level analysis are shown in Table IV. Column 1 of Table IV shows the basic model, while Column 2 includes conglomerate fixed effects. Both columns tell the same story. Consistent with the results in Table II, *RelatedSegmentProfitability* is a large and significant predictor of NPE targeting. But so is *UnrelatedSegmentProfitability*. In other words, NPEs seem not to care where their proceeds come from; an NPE's probability of suing a

³¹The concordance file we use was developed by Silverman (2003) and later improved by Kerr (2008). This concordance has been used in several other studies, including those of McGahan and Silverman (2001) and Mowery and Ziedonis (2001).

³²While we would ideally prefer to measure cash at the segment level in order to make our segment-level analysis completely analogous to the tests in Tables II and III, segment-level cash variables are not reported. Thus, we use profitability (revenues net of costs) at the segment level to proxy for profitability of suit.

firm increases with the firm’s profits even if those profits are derived from segments unrelated to the patent under litigation. In Column 2 of Table IV, we see that the coefficient on *UnrelatedSegmentProfitability*, 0.0265 ($t = 1.99$), implies that, controlling for the profitability of a segment related to the patent allegedly being infringed, a one standard-deviation increase in a completely unrelated segment’s profitability increases the chance of being sued by 0.58% (relative to a mean of 3.18%). This compares to an increase in probability of 0.71% for the same size increase in a related segment’s profitability ($t = 2.18$). In contrast, when we run the analogue of Column 1 and 2 for PE firms, we see that *UnrelatedSegmentProfitability* is not related to PE litigation activity.

In sum, the results in Table IV provide additional, finely measured evidence that NPEs behave opportunistically by targeting cash indiscriminately—NPEs target related cash and unrelated cash at essentially the same rate.

4.4 Which NPEs are Driving Cash Targeting? Large Aggregators vs. Small Inventors

NPEs take many organizational forms. We next explore whether the cash-targeting behavior seen in Tables II and IV varies by NPE type. As mentioned in Section 3, we exclude universities and NCEs from the sample. This leaves essentially two main categories of patent asserters in our data: *patent assertion entities (PAEs)* and *small inventors*. In our sample, 87.98% of the 21,300 cases have a patent assertion entity as a plaintiff, while small inventors bring 9.63% of cases.³³ Detailed information on plaintiff types, as well as comparison to other samples, is provided in Appendix Table A4.

In Table V, we decompose the results shown in Table II by NPE type. In Column 1 of Table V, the regressand takes a value of 1 if the firm is sued by a patent assertion entity (PAE). In Column 2, we reestimate the same specification with the regressand defined as 1

³³The remaining 2.38% of cases are not included in the analysis presented in this section, as those cases could not be clearly assigned to either group.

when a firm is sued by a small inventor.

From Table V, we see that the entire cash-targeting effect is driven by patent assertion entities. Columns 1 of Table V show that in cases where a patent assertion entity is involved, *CashLevel* and *CashShock* are large and significant predictors of litigation action. In contrast, in cases involving small innovators, neither *CashLevel* nor *CashShock* are significant predictors of targeting, and both have coefficients that are close to 0. Consequently, we see that patent assertion entities are responsible for nearly the entire magnitude of the coefficients on both cash variables shown in Table II.

4.5 Comparing the Types of Patents Asserted by NPEs and PEs

We now compare the types of patents asserted by NPEs to those asserted by PEs. There are many ways to parameterize patent similarity; we use a number of different metrics and measures of patent quality in comparing the patents asserted by NPEs to those asserted by PEs. First, following Love (2014), we examine whether NPEs disproportionately assert patents just before those patents' expiration dates. We show the breakdown of patent age between NPEs and PEs in Table VI. From this table, we first see that NPE-asserted patents are significantly older than PE-asserted patents. From the first row of Table VI, we see that NPEs assert patents that are 25% older than those PEs assert ($t = 20.91$).

NPEs not only appear to be asserting patents closer to expiration than PEs, but relative to PEs, NPEs are much more likely to sue many times on any given asserted patent. In the second row of Table VI, for instance, we see that NPEs litigate each patent they assert 4.5 times as frequently as PEs do (13.02 times for NPEs vs. 2.84 times for PEs ($t = 59.76$)).

Using a recently assembled dataset which contains information on the number of issued, pending, abandoned patents by NBER technology group for each month (Marco, Carley, Jackson, and Myers (2015)), we see that patents asserted in NPE cases are more likely to be issued at times when the USPTO issues more patents compared to total pending and abandoned applications ($t = 13.74$)—that is, at times when the USPTO is especially busy.

Furthermore, and consistent with NPEs asserting broad patents, we also find that patents asserted by NPEs have a significantly higher number of associated technology classes.³⁴

When we compare the linguistic content of the claims in patents asserted by NPEs and PEs, we find striking differences. Consistent with the previous finding that NPE patents are broader than PE patents, evidence suggests NPE patents contain significantly more independent claims than PE patents do (4.86 vs. 3.80 ($t = 21.11$)) and more dependent claims (29.98 vs. 21.19 ($t = 22.92$)). Moreover, the descriptions of patents asserted by NPEs contain more words, both in dependent and independent claims, than are found in patents asserted by PEs. For instance, an average patent asserted by NPEs contains 802 words in its independent claims, whereas an average patent asserted by PE contains 531 words (with the difference of 271 words highly significant ($t = 26.54$)). The same holds true for lengthier-worded dependent claims, with a difference of 361 words ($t = 26.54$)—802 for NPEs vs. 531 for PEs.

Collectively, our results suggest NPEs assert patents that are significantly different from those of PEs. In particular, NPEs assert patents that are broader in scope and wordier. In addition, they assert these broader patents significantly more aggressively, and closer to the expiration of patent rights.

4.6 Geography of NPE Litigation

Even if NPEs target lawsuits opportunistically, this need not show up in outcomes, as courts remain the ultimate arbiters of patent infringement. Thus, for NPEs to target cash successfully, they would—at minimum—need a credible threat of having courts rule in their favor sufficiently often.

Figure 2 shows the geography of NPE patent litigation in the United States. Unsurprisingly, some well-known innovation hubs (e.g., Silicon Valley) have large amounts of NPE IP litigation. However, validating common anecdotal accounts, we see that the preponderance of NPE patent litigation (over 30% of all cases) takes place in the Eastern District of Texas (Marshall,

³⁴Patents asserted by NPEs (resp. PEs) on average have 5.86 (resp. 4.83) associated technology classes ($t = 21.50$).

TX). Eastern Texas is not a major innovation center; rather, its courts are favored by NPEs because they are perceived to be plaintiff-friendly (both anecdotally and because of specific rules regarding judgment (Leychkis (2007))).

The practice of “forum shopping” (i.e., “choosing the most favorable jurisdiction or court in which a claim might be heard” (Garner and Black (2004))) is not unique to IP litigation. However, again, even within the space of IP litigation, we see that NPEs seem to “forum shop” a uniquely large amount. NPE cases and PE cases have very different geographic patterns. For instance, when we run a Wilcoxon test comparing the geographic distributions of NPE and PE litigation, we see a significant difference ($z = 2.35$), with, again, NPEs more concentrated in East Texas.

4.7 Probability of Paying

In this section, we test whether proxies for firm’s readiness (and ability) to stave off NPE litigation impact firms’ probabilities of being targeted. We create two measures: one measure counting the number of lawyers firms have at their disposal, and the second counting how busy firms are with non-IP litigation actions.

The idea of the first measure—number of lawyers—is that large legal teams may serve to deter NPEs because they could to prolong the court (or settlement) process. The second measure—how busy the firm is with outside litigation—is meant capture the within-firm resource constraint on time and costs spent battling litigation. We expect that if NPEs opportunistically target firms that are unlikely to be able to defend themselves, then (1) having many lawyers should deter suits (so there should be a negative coefficient on the number of lawyers), and (2) being involved in extraneous, non-IP cases should draw more suits (so the associated coefficient should be positive).

In order to measure firms’ legal teams, we extract data from the ALM Legal Intelligence Database. We obtain a list of all law firms and their clients from ALM Legal Intelligence between 2005 and 2012. Then, we follow the procedure outlined in Appendix Table 2 to

define a dummy variable *IPLegalTeamSize* which takes a value of 1 if the firm employs more IP focused law firms than a comparable firm with similar characteristics. Our second measure, *OngoingCases*, measures the existence and number of reported, ongoing non-IP-related litigation actions. From Table VII, we see that controlling for all other characteristics, NPEs are less likely to sue a firm with more legal representation. The coefficient on *IPLegalTeamSize* in Column 2 implies that a one standard deviation increase in IP legal team size decreases the likelihood of suit by 7.2% ($t = 2.13$). NPEs are also more likely to target firms that are busy with ongoing, non-IP litigation. The Column 2 coefficient on *OngoingCases* of 0.0171 ($t = 2.38$) implies that firms that are occupied with large number of non-IP litigation cases are 19% more likely to be targeted by NPEs.

The empirical specification considered in this section also provides evidence against a precautionary savings interpretation of the cash-targeting results shown in Table II. If precautionary savings were driving the relationship seen in Table II, then we would expect the coefficient on *LegalTeamSize* to be positive—firms saving cash to stave off infringement litigation should also be growing their legal teams(!). (At the very least, under the precautionary savings hypothesis, we would not expect the negative and significant relationship observed in the data.) To believe the precautionary savings hypothesis, we would need to believe that firms are raising cash to preempt litigation at the same time as they are actively *decreasing* their legal representation; this seems unlikely. Instead, the findings as a whole appear more consistent with NPEs acting opportunistically—targeting cash-rich firms that are more likely to settle, either because they have recently reduced their legal teams or because they are embroiled in outside litigation.

4.8 Sum of Evidence

In summary, our empirical evidence shows that:

1. NPEs specifically target litigation against firms that are flush with cash.

2. Cash-targeting appears to be unique to NPE IP litigation.
 - Cash is neither a significant positive predictor of PE IP lawsuit targeting, nor of non-IP lawsuit targeting (rather, these other classes of lawsuits appear to have most of the R^2 driven by infractions themselves).
 - More generally, NPE behavior is different from PE behavior even conditioning on the same type of infraction (alleged IP infringement).
3. NPEs target cash unrelated to the alleged infringement with essentially the same frequency that they target cash related to the alleged infringement.
4. The cash-targeting behavior we observe is driven by large aggregator NPEs, and is not the behavior of small innovators.
5. The patents NPEs assert are seemingly different in quality from those asserted by PEs (in particular, on average NPEs assert patents that broader and closer to expiry). Moreover, NPEs assert patents more aggressively than PEs do.
6. NPEs appear to forum shop, trying the preponderance of their cases in a single district in Texas.
7. NPEs target firms that may have reduced ability to defend themselves against litigation.

While none of our results alone proves opportunistic legal behavior (patent trolling) on the part of NPEs, the sum of the evidence to this point appears most consistent with NPEs behaving as patent trolls.

In line with our evidence, there have been increasingly frequent high-profile anecdotal accounts of trolling by NPEs (nearly always litigated in Marshall, Texas). For instance, Lumen View Technology LLC sued numerous online dating companies for alleged infringement on a patent on computerized matchmaking that United States District Judge Denise Cote later pronounced to be obviously invalid. “There is no inventive idea here,” Judge Cote

declared, pointing out that “matchmaking” is literally ancient (Mullin (November 23, 2013)). Meanwhile, MPHJ Technology Investments sued over sixteen thousand small businesses (along with a number of branches of the United States Government) alleging infringement on a patent covering “scan-to-email” functionality. Many of MPHJ’s cases were not only dismissed, but prompted countersuits for deceptive practices (Mullin (January 14, 2014)).

We conduct several robustness checks on our analysis in Section 4.9, and then assess the impact of NPEs on real outcomes in Section 5. We tie back to the theory and discuss welfare implications in Section 6.

4.9 Robustness Tests

In this section, we provide a number of robustness tests, including an out-of-sample test and a number of additional specifications.

4.9.1 Out-of-Sample Test

As mentioned in Section 3, the analyses discussed in the text use data from RPX Corporation, a company that tabulates information on NPE behavior. While the data is all sourced from public documents (namely the USPTO and public court records), RPX retains the dataset itself as proprietary. Cotropia, Kesan, and Schwartz (2014) recently hand-coded and classified NPE IP litigation events for a two-year sample (2010 and 2012), and made this data publicly available at www.npdata.com.

We have re-run all of our analyses on the Cotropia, Kesan, and Schwartz (2014) data; the results of this out-of-sample test are shown in Appendix Table A4. We find the same results using the Cotropia, Kesan, and Schwartz (2014) data as with the RPX data: cash is a large and significant predictor of NPE targeting, and this behavior is driven by PAEs.³⁵

³⁵The estimated magnitudes on cash are actually a bit larger in the Cotropia, Kesan, and Schwartz (2014) sub-sample (given the larger standard deviation of cash in later 2010-2012 period), with the coefficient on large aggregators being roughly triple the size of small innovators, and statistically significantly larger. We also calculate the overlap rate between the RPX and Cotropia, Kesan, and Schwartz (2014) samples for the two years available (2010 and 2012) and find a roughly 90% overlap.

4.9.2 Thicket Industries and Additional Specifications

Patent thickets are dense, overlapping webs of patents that make it difficult to commercialize because products may overlap with large numbers of patented technologies. Certain industries are known to be more prone to patent thickets, and those industries themselves have been linked to strategic patenting behavior (Bessen and Meurer (2013)). We test whether the cash-targeting behavior of NPEs differs between thicket- and non-thicket industries.³⁶ Columns 1-2 of Table VIII, Panel A show the results.

Column 3 runs the same analysis excluding IT firms (SIC Code 35 (e.g., Apple and IBM) and SIC Code 73 (e.g., Yahoo! and Ebay)); again, cash a strong determinant of targeting, nearly identical in magnitude and significance. Column 4 uses a cash measure that incorporates marketable securities of the firm. The economic magnitude implied by the coefficient of *CashLevel* in this specification is similar to our baseline specification. Column 5 allows additional non-linearities in cash (cash level squared and cubed); neither loads significantly, and allowing non-linearity does not appear to have an impact on the estimated magnitude or significance of the *CashLevel* and *CashShock* coefficients. In this specification, we also include a new variable (*FinancialConstraints*) that measures how financially constrained firms are, and find that it is not a statistically significant predictor of NPE targeting.³⁷

Panel B of Table VIII shows a number of additional specifications. First, throughout the paper we have used whether or not a firm is sued by an NPE in a given year (*SuedByNPE*). However, a number of firms are sued multiple times by different (or even the same) NPEs within a single year. In Table VIII, Panel B we replace the dependent variable with the number of times a firm is sued by an NPE in a given year. We find similar results to those presented in Table II: *CashLevel* and *CashShock* are large and significant predictors of the number of times a firm is sued in a given year (both in OLS and Tobit specifications).

³⁶We define thicket industries as those having two-digit SIC codes of 35, 36, 38 and 73, following Bessen and Meurer (2014). These industries encompass software, semiconductors, and electronics, and include firms such as Apple, Google, and Intel.

³⁷Here, we use the Hadlock and Pierce (2010) financial constraints index of firms' constraints on accessing the external funds.

For instance, Column 1 of Table VIII, Panel B shows a coefficient on *CashLevel* of 0.4439 ($t = 2.71$), implying that a one standard-deviation increase in cash doubles the number of times a firm is targeted by NPEs. Additionally, Columns 3 and 4 of Table VIII, Panel B show the base categorical variable specification of the dependent variable (*SuedByNPE*), but in Probit and Logit regression estimations. Again cash remains a large and significant predictor of NPE targeting behavior.

5 Impact of NPE Litigation on Real Outcomes

Up to this point, we have examined which firms NPEs target, and when. We now examine the real impacts of NPE litigation on the firms being targeted. Of course the difficulty in obtaining any causal estimates here is that we have a clear selection problem (that is, it might be the case that the firms that NPEs target experience some outcome not because of NPE litigation, but because they share some common unobservable characteristic). We attempt to alleviate selection concerns somewhat by conditioning on being targeted—we compare two groups of firms, both selected to be sued by NPEs. Specifically, we compare all firms targeted by NPEs, separating targeted firms specifically according to whether (1) they were forced to pay out to NPEs (they either lost in court or settled) or (2) the cases against them were dismissed (including when the court ruled against the NPE).³⁸ We test whether losing to an NPE and having an NPE lawsuit dismissed lead in different directions in terms of future R&D productivity. Specifically, we focus on how R&D expenditures on projects differ (pre- and post-litigation) among the two classes of targeted firms.

Table IX reports the difference-in-differences results. From Panel A of Table IX, we see that losing to an NPE has a large and negative impact on future R&D activities—again, even conditioning on being selected for litigation. We compare average annual R&D expense two years following the litigation to average annual R&D expense two years before the litigation.

³⁸Following Allison, Lemley, and Walker (2010), we exclude case outcomes such as “stay,” “transfer,” and “procedural disposition.”

To get an idea of the effect magnitude, the results shown in Panel A imply that firms that lose to a large aggregator NPE (Settled + Won by NPE) invest significantly less in R&D in the years following the loss (\$163 million less, $t = 7.18$) relative to firms that were also targeted by NPEs but won (Dismissed + Lost by NPE).

Panel A also shows that we see no such patterns for PE vs. PE cases—unlike firms that lose to NPEs, firms that lose to PEs show no reduction in R&D investment. Panel B of Table IX runs parallel trends analysis, showing that the firms in our comparison groups had similarly-moving R&D expenditures prior to the NPE lawsuits.

Lastly, Panel C of Table IX shows an analysis of the same firms pre- and post-difference-in-differences analysis, but in a regression framework where more firm-level determinants of R&D can be included. From Panel C, we see that losing to a large aggregator NPE (again, selecting on being targeted) leads to 1.73% reduction in future R&D expense (scaled by assets).³⁹ Considering the mean of dependent variable is 8.7%, this magnitude is economically large and statistically significant, representing a roughly 20% reduction ($t = 2.43$) in R&D investment. Again, from Column 3 of Table IX, Panel C, we see that there is no resultant reduction in R&D expenditure following losses in PE vs. PE cases.

In all, the evidence in this section strongly supports the idea that NPEs have a real and negative impact on innovation of United States firms, and that within the IP space—like the cash-targeting behavior we have observed—the negative impact on R&D is unique to NPE lawsuits.

6 Discussion

Our results show that NPEs on average sue firms that have substantial cash holdings. While we cannot observe directly whether infringement has occurred in a given case, our results suggest that cash—rather than policing infringement—drives NPE targeting. Cash is a

³⁹In these tests we control for *CitationCommonality*, a pairwise patent similarity measure provided to us by Ambercite (see Appendix Table A1).

first-order determinant of NPE IP litigation even when that cash is unrelated to the alleged infringement, and even though cash is neither a key driver of PE IP suits nor of non-IP litigation. Meanwhile, NPEs appear to bring lower quality lawsuits, and there is some evidence that NPEs are actively forum shopping.

NPE litigation has a real negative impact on innovation at targeted firms: PEs substantially reduce their innovative activity after settling with NPEs (or losing to them in court). Measuring NPEs' *net* impact on innovation, however, requires accounting for the potential of NPE litigation to positively incentivize innovation by individual inventors. Unfortunately, because most settlement values are not disclosed, we cannot measure the full size of the transfer from PEs to NPEs (much less the transfer from NPEs to end inventors). Furthermore, we cannot measure the increase in innovation incentives that might come from PEs being less likely to infringe (given NPE behavior). Thus, we cannot explicitly measure the potential welfare gains from NPE litigation. Nevertheless, we note that as our theoretical model suggests, the benefits of NPEs in terms of increased innovation incentives for end inventors (both the direct benefits through lawsuits, and the indirect benefits in terms of enhanced licensing potential) depend on the *fraction* of NPE profits passed through to end inventors.

There are three pieces of empirical evidence that somewhat speak to the impact of NPEs on small inventors' innovation incentives. First, Bessen, Ford, and Meurer (2011) directly estimate the pass-through parameter that our theory highlights as the key mediator of NPEs' benefits for end inventors. Bessen, Ford, and Meurer (2011) find very low pass-through, estimating that only five cents of every dollar in damages paid by PEs to NPEs makes it back to end innovators. Thus, one would need to believe in a large multiplier (summing both direct and indirect spillover effects) to justify, from a social-welfare perspective, NPE litigation practices as an efficient mechanism to transfer the marginal dollar of innovative capital—even if all NPE lawsuits were well-founded. Second, Feldman and Lemley (2015) find evidence that patent licensing does little or nothing to increase innovation—irrespective of whether NPEs or PEs are the licensors. Lastly, we conduct a simple empirical analysis,

presented in Table X, in which we measure changes in innovation outcomes in the *exact* technology areas in which NPE litigation is most frequent. In NPE-heavy areas, both the direct and indirect benefits of NPE litigation should be largest, but Table X shows that there has been no observable increase in innovation by small innovators.

The marginal welfare impact of NPEs is also largely determined by the frequency with which NPEs successfully bring “nuisance” cases instead of meritorious ones.⁴⁰ As our model suggests, NPE nuisance suits stand to crowd out socially valuable innovation (and possibly to *induce* socially inefficient infringement), without any measurable social gains.

7 Conclusion

We provide the first large-sample evidence on the behavior and impact of NPEs. Our theoretical model illustrates that while NPE litigation can reduce infringement and support small inventors, as NPEs become effective at bringing opportunistic lawsuits, they can inefficiently crowd out some firms that would otherwise produce welfare-enhancing innovations without engaging in infringement. Our complementary empirical analysis shows that on average, NPEs appear to behave as opportunistic patent trolls. They sue cash-rich firms—a one standard deviation increase in cash holdings increases a firm’s chance of being targeted by NPE litigation more than twofold. By contrast, cash is neither a key driver of IP lawsuits by PEs, nor of any other type of litigation against firms. The cash-targeting behavior we observe is driven by large aggregator NPEs, and is not the behavior of small innovators. NPEs even target conglomerate firms that earn their cash from segments having nothing to do with their allegedly infringing patents. (Profitability in unrelated businesses is almost as predictive of an NPE suit as is profitability in business segments related to NPE-alleged patent infringement.) We find further suggestive evidence of NPE opportunism, such as late-stage litigation, forum shopping, and targeting of firms that may have reduced ability to

⁴⁰From the model of NPE behavior in Section 2, this corresponds to the relationship between \underline{p}_n (NPEs’ ability to bring groundless suits) and \bar{p}_n (NPEs’ ability to bring meritorious suits).

defend themselves against litigation. We find that this NPE litigation has a real negative impact on innovation at targeted firms: PEs substantively reduce their innovative activity after settling with NPEs (or losing to them in court). Moreover, we neither find any markers of significant NPE pass-through to end innovators, nor of a positive impact of NPEs on innovation in the industries in which they are most prevalent in litigating infringement.

Setting intellectual property policy regarding patent assertion is first-order. If widespread opportunistic patent litigation makes the United States a less desirable place to innovate, then innovation and human capital—and the returns to that innovation and human capital—will likely flee overseas. That said, innovators will also leave if they feel they are not protected from large, well-funded interests that might infringe on innovative capital without recompense. Our results provide evidence that NPEs—in particular, large patent aggregators—on average do not protect innovation. Rather, our results are consistent with the view that, on average, NPEs behave as patent trolls that chase cash and negatively impact innovative activities at targeted firms. Given our findings, the marginal policy response should be to more carefully limit the power of NPEs or, in the framework of our model, introduce cost-shifting or screening measures to reduce the incentive to bring nuisance suits.

References

- ABRAMS, D. S., U. AKCIGIT, AND J. POPADAK (2013): “Patent Value and Citations: Creative Destruction or Strategic Disruption?,” NBER Working Paper No. 19647.
- ALLISON, J. R., M. A. LEMLEY, AND J. WALKER (2010): “Patent quality and settlement among repeat patent litigants,” *Georgetown Law Journal*, 99, 677–712.
- ARENA, M., AND B. JULIO (2011): “Litigation Risk, Cash Holdings, and Corporate Investment,” Marquette University and London Business School Working Paper.
- BEATTY, A., J. WEBER, AND J. J. YU (2008): “Conservatism and debt,” *Journal of Accounting and Economics*, 45(2), 154–174.
- BESSEN, J. E., J. FORD, AND M. J. MEURER (2011): “The Private and Social Costs of Patent Trolls,” *Regulation*, 34(4), 26–35.
- BESSEN, J. E., AND M. J. MEURER (2006): “Patent Litigation with Endogenous Disputes,” *American Economic Review*, 96(2), 77–81.
- (2014): “The Direct Costs from NPE Disputes,” *Cornell Law Review*, 99(2), 387–424.
- BUDISH, E. B., B. N. ROIN, AND H. L. WILLIAMS (2015): “Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials,” *American Economic Review*, 105(7), 2044–2085.
- CHENG, A., H. HE HUANG, Y. LI, AND G. LOBO (2010): “Institutional monitoring through shareholder litigation,” *Journal of Financial Economics*, 95(3), 356–383.
- CHIEN, C. V. (2013a): “Patent Assertion and Startup Innovation,” Report of the New America Foundation’s Open Technology Institute.
- (2013b): “Patent Trolls by the Numbers,” Santa Clara University Legal Studies Research Paper No. 08-13.

- (2014): “Startups and Patent Trolls,” *Stanford Technology Law Review*, 17, 461–506.
- CHOI, J. P., AND H. GERLACH (2014): “A Model of Patent Trolls,” Michigan State University Working Paper.
- COOTER, R. D., AND D. L. RUBINFELD (1989): “Economic analysis of legal disputes and their resolution,” *Journal of Economic Literature*, 27(3), 1067–1097.
- COTROPIA, C. A., J. P. KESAN, AND D. L. SCHWARTZ (2014): “Unpacking patent assertion entities (PAEs),” *Minnesota Law Review*, 99, 649–703.
- DAUGHETY, A. F., AND J. F. REINGANUM (2000): “On the economics of trials: Adversarial process, evidence, and equilibrium bias,” *Journal of Law, Economics, and Organization*, 16(2), 365–394.
- EXECUTIVE OFFICE OF THE PRESIDENT (2013): “Patent Assertion and U.S. Innovation,” https://www.whitehouse.gov/sites/default/files/docs/patent_report.pdf.
- FELDMAN, R. (2014): “Patent Demands & Startup Companies: The View from the Venture Capital Community,” *Yale Journal of Law & Technology*, 16, 236–284.
- FELDMAN, R., AND M. A. LEMLEY (2015): “Do Patent Licensing Demands Mean Innovation?,” *Iowa Law Review*, 101, 137–189.
- FRANCIS, J., D. PHILBRICK, AND K. SCHIPPER (1994): “Shareholder litigation and corporate disclosures,” *Journal of Accounting Research*, 32(2), 137–164.
- GALASSO, A., AND M. SCHANKERMAN (2010): “Patent thickets, courts, and the market for innovation,” *RAND Journal of Economics*, 41(3), 472–503.
- GALASSO, A., M. SCHANKERMAN, ET AL. (2015): “Patents and Cumulative Innovation: Causal Evidence from the Courts,” *Quarterly Journal of Economics*, 130(1), 317–369.

- GALASSO, A., M. SCHANKERMAN, AND C. J. SERRANO (2013): “Trading and enforcing patent rights,” *RAND Journal of Economics*, 44(2), 275–312.
- GARNER, B. A., AND H. C. BLACK (2004): *Black’s Law Dictionary*. Thomson/West.
- HADLOCK, C. J., AND J. R. PIERCE (2010): “New evidence on measuring financial constraints: Moving beyond the KZ index,” *Review of Financial studies*, 23(5), 1909–1940.
- HANLEY, K. W., AND G. HOBERG (2012): “Litigation risk, strategic disclosure and the underpricing of initial public offerings,” *Journal of Financial Economics*, 103(2), 235–254.
- HAY, B., AND K. E. SPIER (1998): “Settlement of litigation,” in *The New Palgrave Dictionary of Economics and the Law*, ed. by P. Newman, vol. 3, pp. 442–451. Palgrave Macmillan.
- HELMERS, C., B. LOVE, AND L. MCDONAGH (2013): “Is there a patent troll problem in the UK,” *Fordham Intellectual Property Media & Entertainment Law Journal*, 24, 509–553.
- JAYARAMAN, S., AND T. MILBOURN (2009): “Does equity-based CEO compensation really increase litigation risk?,” Working paper, Washington University.
- JOHNSON, M. F., R. KASZNIK, AND K. K. NELSON (2000): “Shareholder wealth effects of the private securities litigation reform act of 1995,” *Review of Accounting Studies*, 5(3), 217–233.
- KERR, W. R. (2008): “Ethnic scientific communities and international technology diffusion,” *Review of Economics and Statistics*, 90(3), 518–537.
- KIEBZAK, S., G. RAFERT, AND C. E. TUCKER (2016): “The effect of patent litigation and patent assertion entities on entrepreneurial activity,” *Research Policy*, 45(1), 218–231.
- KOGAN, L., D. PAPANIKOLAOU, A. SERU, AND N. STOFFMAN (2012): “Technological innovation, resource allocation, and growth,” NBER Working Paper No. 17769.

- LEMLEY, M. A., AND A. D. MELAMED (2013): “Missing the Forest for the Trolls,” *Columbia Law Review*, 113(8), 2117–2189.
- LEMLEY, M. A., AND C. SHAPIRO (2005): “Probabilistic Patents,” *Journal of Economic Perspectives*, 19(2), 75–98.
- (2006): “Patent Holdup and Royalty Stacking,” *Texas Law Review*, 85, 1991–2163.
- LERNER, J. (2009): “The Empirical Impact of Intellectual Property Rights on Innovation: Puzzles and Clues,” *American Economic Review*, 99(2), 343–348.
- LEYCHKIS, Y. (2007): “Of Fire Ants and Claim Construction: An Empirical Study of the Meteoric Rise of the Eastern District of Texas as a Preeminent Forum for Patent Litigation,” *Yale Journal of Law & Technology*, 9, 193–232.
- LOVE, B. J. (2014): “An Empirical Study of Patent Litigation Timing: Could a Patent Term Reduction Decimate Trolls Without Harming Innovators?,” *University of Pennsylvania Law Review*, 161, 1309–1359.
- LOWRY, M., AND S. SHU (2002): “Litigation risk and IPO underpricing,” *Journal of Financial Economics*, 65(3), 309–335.
- MARCO, A. C., M. CARLEY, S. JACKSON, AND A. F. MYERS (2015): “The USPTO Historical Patent Data Files: Two Centuries of Innovation,” Working Paper, United States Patent and Trademark Office.
- MCGAHAN, A. M., AND B. S. SILVERMAN (2001): “How does innovative activity change as industries mature?,” *International Journal of Industrial Organization*, 19(7), 1141–1160.
- MOWERY, D. C., AND A. A. ZIEDONIS (2001): “The geographic reach of market and non-market channels of technology transfer: Comparing citations and licenses of university patents,” NBER Working Paper No. 8568.

- MULLIN, J. (January 14, 2014): “Patent stunner: Under attack, nation’s most notorious “troll” sues federal gov’t,” *Ars Technica*.
- (November 23, 2013): “FindTheBest destroys “matchmaking” patent, pushes RICO case against troll,” *Ars Technica*.
- POLINSKY, A. M., AND S. SHAVELL (1989): “Legal Error, Litigation, and the Incentive to Obey the Law,” *Journal of Law, Economics and Organization*, 5(1), 99–108.
- ROGERS, J. L., AND A. VAN BUSKIRK (2009): “Shareholder litigation and changes in disclosure behavior,” *Journal of Accounting and Economics*, 47(1), 136–156.
- SAKAKIBARA, M., AND L. BRANSTETTER (2001): “Do Stronger Patents Induce More Innovation? Evidence from the 1988 Japanese Patent Law Reforms,” *RAND Journal of Economics*, 32(1), 77–100.
- SCHWARTZ, D. L., AND J. P. KESAN (2014): “Analyzing the role of non-practicing entities in the patent system,” *Cornell Law Review*, 99(2), 425–456.
- SCOTT MORTON, F. M., AND C. SHAPIRO (2014): “Strategic Patent Acquisitions,” *Antitrust Law Journal*, 79(2), 463–500.
- SEETHARAMAN, A., F. A. GUL, AND S. G. LYNN (2002): “Litigation risk and audit fees: Evidence from UK firms cross-listed on US markets,” *Journal of Accounting and Economics*, 33(1), 91–115.
- SHRESTHA, S. K. (2010): “Trolls or Market-makers? An empirical analysis of nonpracticing entities,” *Columbia Law Review*, 110, 114–160.
- SHU, S. Z. (2000): “Auditor resignations: Clientele effects and legal liability,” *Journal of Accounting and Economics*, 29(2), 173–205.
- SILVERMAN, B. S. (2003): *Technological Resources and the Logic of Corporate Diversification*. Routledge.

- SKINNER, D. J. (1994): “Why firms voluntarily disclose bad news,” *Journal of Accounting Research*, 32(1), 38–60.
- (1997): “Earnings disclosures and stockholder lawsuits,” *Journal of Accounting and Economics*, 23(3), 249–282.
- SMEETS, R. (2015): “Does Patent Litigation Reduce Corporate R&D? An Analysis of US Public Firms,” Working Paper, Rutgers University.
- SPIER, K. (2005): “Economics of Litigation,” in *The New Palgrave Dictionary of Economics*, ed. by S. Durlauf, and L. Blume. Macmillan.
- TUCKER, C. E. (2014): “Patent Trolls and Technology Diffusion: The Case of Medical Imaging,” Working Paper, Massachusetts Institute of Technology.
- UNITED STATES GOVERNMENT ACCOUNTABILITY OFFICE (2013): “Assessing Factors That Affect Patent Infringement Litigation Could Help Improve Patent Quality,” GAO-13-465.
- UNITED STATES PATENT AND TRADEMARK OFFICE (2015): “Request for Comments on Enhancing Patent Quality,” *Federal Register*, 80, 6475–6481.
- WILLIAMS, H. L. (2013): “Intellectual Property Rights and Innovation: Evidence from the Human Genome,” *Journal of Political Economy*, 121(1), 1–27.
- (2015): “Intellectual Property Rights and Innovation: Evidence from Health Care Markets,” in *Innovation Policy and the Economy*, ed. by J. Lerner, and S. Stern, vol. 16. University of Chicago Press.

Table I. Summary Statistics, 2005–2015

Panel A of this table presents summary statistics on the firms included in the tests. Appendix Table A1 contains the definitions of the variables we use. Total Assets, Market Value, R&D Expense, and Cash is reported in billion USD. In Panel B, we tabulate number of dockets reported in the RPX database by year. RPX records information on cases in which the plaintiff is an NPE or an Operating Company (PE). According to RPX, an NPE is an entity that derives or plans to derive the majority of its revenue from the licensing or enforcement of patents and for which RPX has been unable to obtain verifiable evidence that the entity sells products or services that would make it vulnerable to patent counter-assertion. NPEs include the following organizational forms: (1) patent assertion entities (Patent Asserter), entities believed to earn revenue predominantly through asserting patents, (2) individual inventors (Small Inventor), (3) non-competing entities (NCEs), operating companies asserting patents outside their areas of products or services, and (4) universities and research institutions. In the last column of Panel B, we tabulate the number of observations in a different database, Lex Machina, that also provides patent litigation information.

Panel A. Summary Statistics on Firm Characteristics

| | Mean | Median | St. Dev | P05 | P25 | P75 | P95 |
|-------------------|--------|--------|---------|--------|--------|-------|--------|
| Total Assets | 13.991 | 0.719 | 108.401 | 0.023 | 0.165 | 3.075 | 32.143 |
| Market Value | 3.815 | 0.454 | 16.389 | 0.019 | 0.112 | 1.866 | 15.483 |
| B/M | 2.965 | 0.599 | 66.765 | 0.117 | 0.339 | 1.000 | 3.787 |
| Past Return | 0.139 | 0.065 | 0.706 | -0.622 | -0.191 | 0.325 | 1.077 |
| R&D Expense | 0.077 | 0.000 | 0.510 | 0.000 | 0.000 | 0.011 | 0.184 |
| Number of Patents | 55.62 | 0.000 | 540.80 | 0.000 | 0.000 | 0.000 | 97.00 |
| Cash | 0.579 | 0.040 | 4.272 | 0.001 | 0.010 | 0.167 | 1.776 |
| Sued by NPE | 0.086 | 0.000 | 0.280 | 0.000 | 0.000 | 0.000 | 1.000 |
| Sued by PE | 0.046 | 0.000 | 0.209 | 0.000 | 0.000 | 0.000 | 0.000 |

Panel B. Sample Description

| | RPX | | | | | | Lex Machina |
|------|-----------------|----------------|-----|------------|-------------------|-------|-------------|
| | NPE | | PE | | | Total | NPE & PE |
| | Patent Asserter | Small Inventor | NCE | University | Practicing Entity | | Total |
| 2005 | 381 | 172 | 11 | 12 | 1,917 | 2,493 | 2,523 |
| 2006 | 499 | 143 | 16 | 11 | 1,914 | 2,583 | 2,581 |
| 2007 | 658 | 173 | 16 | 11 | 1,831 | 2,689 | 2,775 |
| 2008 | 618 | 222 | 8 | 15 | 1,651 | 2,514 | 2,573 |
| 2009 | 633 | 197 | 12 | 16 | 1,634 | 2,492 | 2,547 |
| 2010 | 787 | 174 | 19 | 17 | 1,693 | 2,690 | 2,770 |
| 2011 | 1,520 | 183 | 16 | 14 | 1,813 | 3,546 | 3,575 |
| 2012 | 3,319 | 161 | 107 | 31 | 1,764 | 5,382 | 5,455 |
| 2013 | 3,831 | 230 | 9 | 71 | 1,873 | 6,014 | 6,114 |
| 2014 | 2,881 | 245 | 63 | 22 | 1,722 | 4,933 | 5,070 |
| 2015 | 3,613 | 152 | 3 | 8 | 1,809 | 5,585 | 5,818 |

Table II. Cash and Probability of Being Sued

In this table, we use a linear probability model to estimate the probability of being sued by an NPE. The outcome variable, Sued by NPE, is a dummy equal to 1 if the firm was litigated by an NPE in a given year. RPX data allows us to observe the type of the NPE. We focus on cases in which the NPE is classified as a patent assertion entity (PAE) or a small inventor (INV). Appendix Table A1 contains the definitions of the variables we use. We use log transformation for Total Assets, Market Value, B/M, Patent Stock, Past Return, R&D Expense, and Cash Level. The sample contains firm-year observations between 2005 and 2015. Standard errors, clustered by firm, are reported in parentheses. ***, **, and * denote statistical significance at the 1, 5, and 10 percent levels.

| | Sued by NPE | Sued by NPE | Sued by NPE | Sued by NPE |
|-------------------|------------------------|------------------------|------------------------|-----------------------|
| Cash Level | 0.1021*** (0.0119) | 0.0994*** (0.0119) | 0.0581*** (0.0113) | 0.0565*** (0.0133) |
| Total Assets | -0.0161*** (0.0057) | -0.0149*** (0.0056) | 0.0130** (0.0059) | 0.0199** (0.0084) |
| Market Value | 0.0740*** (0.0075) | 0.0720*** (0.0075) | 0.0610*** (0.0066) | -0.0125 (0.0083) |
| B/M | -0.0045 (0.0048) | -0.0081* (0.0049) | -0.0133*** (0.0048) | -0.0150** (0.0061) |
| Past Return | -0.0063*** (0.0021) | -0.0072*** (0.0023) | -0.0070*** (0.0022) | -0.0006 (0.0025) |
| R&D Expense | 0.1394*** (0.0342) | 0.1398*** (0.0342) | 0.1368*** (0.0295) | 0.1220** (0.0483) |
| Number of Patents | 0.0139*** (0.0026) | 0.0146*** (0.0026) | 0.0149*** (0.0024) | 0.0006 (0.0038) |
| Cash Shock | 0.0199* (0.0106) | 0.0163 (0.0105) | 0.0147* (0.0089) | 0.0167** (0.0081) |
| Firm FE | No | No | No | Yes |
| Industry FE | No | No | Yes | No |
| Year FE | No | Yes | Yes | Yes |
| N | 50,965 | 50,965 | 50,965 | 50,965 |
| R2 | 0.17 | 0.18 | 0.28 | 0.55 |

Table III. Is Cash Targeting a General Feature of Litigation?

In Column 1 of this table, we define Sued by PE to be equal to 1 if a firm faces IP lawsuits from practicing entities (PEs) in a given year. The PE litigation information is obtained from RPX. We obtain litigation information on other types of cases from Audit Analytics database. This database includes material federal civil litigation and class action claims disclosed to the SEC by SEC registrants. Case disclosure comes from the firm, which is responsible for determining whether the case is material for the company. Given the severe penalties involved in not disclosing information that is already public (through PACER), a dominant strategy for a CEO is often disclose not only material information but also potentially non-material information that could later be assessed as being within disclosure guidelines. Furthermore, because our interest lies in the public firms (which are SEC registrants, by definition), Audit Analytics provides a comprehensive database for cases we are interested in. In Columns 2-5, we utilize case classifications reported in Audit Analytics to investigate whether the relation between firm characteristics and NPE litigation differ for different case types. Specifically, in Column 2, we first define the dependent variable to be 1 if the firm is involved in a case related to tort. The other categories include environment, securities, contract, and labor—as defined by PACER. Appendix Table A5 outlines the specific case codes used to identify these cases. We define the dependent variable to be 1 if the firm is sued in the case type specified in the column heading. We use the baseline specification used in Table II to facilitate comparison of coefficients across case types. Standard errors, clustered by firm, are reported in parentheses. ***, **, and * denote statistical significance at the 1, 5, and 10 percent levels.

| | Sued by PE | Tort | Environment | Securities | Contract | Labor |
|---------------------|-----------------------|-----------------------|----------------------|-----------------------|------------------------|---------------------|
| Cash Level | -0.0016 (0.0111) | -0.0228* (0.0122) | -0.0078 (0.0067) | -0.0261** (0.0125) | -0.0343*** (0.0127) | -0.0004 (0.0036) |
| Total Assets | 0.0127* (0.0065) | -0.0158* (0.0084) | 0.0016 (0.0028) | 0.0354*** (0.0097) | 0.0059 (0.0098) | -0.0012 (0.0031) |
| Market Value | 0.0093 (0.0073) | 0.0158** (0.0079) | -0.0019 (0.0026) | 0.0280*** (0.0087) | 0.0265*** (0.0095) | -0.002 (0.0031) |
| B/M | -0.0012 (0.0042) | 0.0100** (0.0042) | 0.0004 (0.0015) | -0.0023 (0.0052) | 0.0143*** (0.0048) | 0.0001 (0.0016) |
| Past Return | -0.0013 (0.0020) | -0.0022 (0.0017) | 0.0005 (0.0007) | -0.0048* (0.0027) | -0.0039 (0.0024) | -0.0008 (0.0008) |
| R&D Expense | -0.0108 (0.0494) | -0.1590** (0.0701) | -0.0019 (0.0158) | -0.0573 (0.0424) | -0.2343*** (0.0538) | -0.0211 (0.0143) |
| Number of Patents | -0.0079** (0.0036) | 0.0056* (0.0034) | 0.0017** (0.0008) | -0.0003 (0.0028) | -0.0018 (0.0034) | 0.0001 (0.0005) |
| Cash Shock | -0.0037 (0.0070) | -0.0055 (0.0073) | 0.0017 (0.0035) | 0.0096 (0.0080) | 0.0221*** (0.0082) | 0.001 (0.0029) |
| Number of Employees | | | | | | 0.0033 (0.0031) |
| Firm FE | Yes | Yes | Yes | Yes | Yes | Yes |
| Year FE | Yes | Yes | Yes | Yes | Yes | Yes |
| N | 50,965 | 42,209 | 42,209 | 42,209 | 42,209 | 41,213 |
| R2 | 0.42 | 0.31 | 0.23 | 0.25 | 0.24 | 0.24 |

Table IV. Probability of Being Sued: Related vs. Unrelated Cash Flows

In this table, we report the probability that a conglomerate is sued by an NPE as a function of the gross profitability of related and unrelated segments. The unit of observation is a conglomerate-segment-year. Sued by NPE is a dummy variable equal to 1 if the conglomerate was litigated by an NPE that year. To identify conglomerate's segments that are related to litigated patents, we use the IPC-to-SIC concordance developed by Silverman (2003). We use Thompson Innovation database to identify IPC classification of each asserted patent. We use financial statements disclosed in segment filings end of each year to collect segment-level information on sales and cost of goods sold and calculate segment gross profitability as the difference. Industry Profitability is the average profitability of all firms in the same four-digit SIC. Standard errors, clustered by conglomerate, are reported in parentheses. ***, **, and * denote statistical significance at the 1, 5, and 10 percent levels.

| | Segment Sued by NPE | Segment Sued by NPE |
|---------------------------------|------------------------|----------------------|
| Related Segment Profitability | 0.1457** (0.0623) | 0.0569** (0.0260) |
| Unrelated Segment Profitability | 0.0835*** (0.0246) | 0.0265** (0.0133) |
| Industry Profitability | -0.0039*** (0.0009) | 0.0008* (0.0005) |
| Conglomerate FE | No | Yes |
| N | 29,405 | 29,405 |
| R2 | 0.02 | 0.44 |

Table V. Cash and Probability of Being Sued: Comparison of PAEs to Small Inventors

In this table, we report the baseline results for different types of NPEs. In Column 1, the regressand takes a value of 1 if the firm is sued by a Patent Asserter. In Column 2, the regressand takes a value of 1 if the firm is sued by a small inventor. Variable definitions are provided in Appendix Table A1. Standard errors, clustered by firm, are reported in parentheses. ***, **, and * denote statistical significance at the 1, 5, and 10 percent levels.

| | Sued by Patent Asserter | Sued by Small Inventor |
|-------------------|-------------------------|------------------------|
| Cash Level | 0.0541*** (0.0135) | 0.0105 (0.0066) |
| Total Assets | 0.0223** (0.0086) | 0.0046 (0.0041) |
| Market Value | -0.0148* (0.0085) | -0.0021 (0.0045) |
| B/M | -0.0170*** (0.0061) | -0.0038 (0.0025) |
| Past Return | -0.0002 (0.0025) | -0.0011 (0.0011) |
| R&D Expense | 0.1376*** (0.0520) | 0.0797* (0.0463) |
| Number of Patents | 0.0024 (0.0038) | -0.0025 (0.0019) |
| Cash Shock | 0.0166** (0.0082) | -0.0044 (0.0052) |
| Firm FE | Yes | Yes |
| Year FE | Yes | Yes |
| N | 50,965 | 50,965 |
| R2 | 0.54 | 0.36 |

Table VI. Asserted Patents' Attributes

In this table, we compare patents asserted in two types of cases: NPE vs. PE, and PE vs. PE. For each patent, we first calculate eight different metrics. Age of Patent when asserted (in months) is the time gap between the dates of litigation filing and patent issuance. Times Asserted measures the number of instances the patents have been asserted through litigation. Issue Time Backlog is the ratio of number of patents issued to sum of patents issued, pending and abandoned, at the time of asserted patent's issue month for the asserted patent's NBER technology group and application time cohort. Scope of Patent is the count of the asserted patent's U.S. technology classes. Number of Independent and Dependent Claims are based on the claims reported in issued patent. We report the mean values and t -test for the difference across patents asserted in NPE vs. PE, and PE vs. PE cases.

| | NPE vs. PE cases | PE vs. PE cases | Difference | t -test |
|---|------------------|-----------------|------------|-----------|
| Age of Patent when asserted (in months) | 92.58 | 76.97 | 15.61 | (20.91) |
| Times Asserted | 13.02 | 2.84 | 10.18 | (59.76) |
| Issue Time Backlog | 0.35 | 0.31 | 0.04 | (13.74) |
| Scope of Patent | 5.86 | 4.83 | 1.03 | (21.50) |
| Number of Independent Claims | 4.86 | 3.80 | 1.06 | (21.11) |
| Number of Words in Independent Claims | 802.27 | 531.58 | 270.69 | (26.54) |
| Number of Dependent Claims | 29.98 | 21.19 | 8.79 | (22.92) |
| Number of Words in Dependent Claims | 1052.41 | 690.86 | 361.55 | (24.04) |
| Number of Asserted Patents | 15,261 | 14,590 | | |

Table VII. Impact of Legal Team Size and Outside (non-IP) Litigation

In this table, we use a linear probability model to estimate the probability of being sued by an NPE. The outcome variable, Sued by NPE, is a dummy equal to 1 if the firm was litigated by an NPE in a given year. We introduce two dummy variables to main specification reported in Table. The first variable, IP Legal Team Size, is a dummy variable that takes a value of 1 if the firm employs more IP focused law firms than a comparable firm with similar characteristics. Appendix Table A2 provides details of IP Legal Team Size calculation. The second variable, Ongoing Cases, takes value of 1 if the number of ongoing litigation the firm is engaged is more than 10% of sum of ongoing litigation of its peer firms in the same industry-year. The sample contains firm-year observations between 2005 and 2012 in the first column because of data limitation. Standard errors, clustered by firm, are reported in parentheses. ***, **, and * denote statistical significance at the 1, 5, and 10 percent levels.

| | Sued by NPE | Sued by NPE |
|-------------------|------------------------|-----------------------|
| Cash Level | 0.0592*** (0.0155) | 0.0563*** (0.0132) |
| Total Assets | 0.0323*** (0.0115) | 0.0197** (0.0083) |
| Market Value | -0.0324*** (0.0103) | -0.0122 (0.0083) |
| B/M | -0.0219*** (0.0072) | -0.0151** (0.0061) |
| Past Return | 0.0009 (0.0029) | -0.0006 (0.0025) |
| R&D Expense | 0.1087* (0.0588) | 0.1213** (0.0485) |
| Number of Patents | 0.0009 (0.0040) | 0.0005 (0.0038) |
| Cash Shock | 0.0200* (0.0104) | 0.0166** (0.0081) |
| Legal Team Size | -0.0062** (0.0029) | |
| Ongoing Cases | | 0.0171** (0.0072) |
| Firm FE | Yes | Yes |
| Year FE | Yes | Yes |
| N | 37,947 | 50,965 |
| R2 | 0.56 | 0.55 |

Table VIII. Robustness Tests

In Panel A of this table, we report the results for several robustness tests. In the first two columns, we report results for thick industries (i.e., industries that are characterized with dense overlapping intellectual property rights and strategic patenting behavior) and non-thicket industries. In Column 3, we exclude IT industry from the sample. We use SIC codes 35, 36, 38 and 73 to identify thick industries. We use SIC codes 35 and 73 to identify IT firms (see Bessen and Meurer (2014)). In Column 4, we use an alternative cash measure (sum of cash and marketable securities) as our main variable of interest. In the last specification, we add three new variables to the baseline specification: cash level squared, cash level cubed and Hadlock and Pierce (2010) financial constraints index. The Hadlock and Pierce (2010) index measures how constrained the firm is in terms of accessing external funds; it combines information on firm asset size, firm asset size squared, and firm age. We use mean firm age for firms whose ages are missing, to keep the sample size constant across specifications (the coefficient of cash is 50% larger when we use the subsample that does not have information on firm age). In Panel B, we report several specifications based on different estimation methods. In the first two columns, we change the left-hand side variable to the number of times sued in a given year and use OLS and Tobit respectively. In the last column, we use Probit models.

Panel A. Thicket Industries vs. Non-Thicket Industries

| | Sued by NPE | Sued by NPE | Sued by NPE | Sued by NPE | Sued by NPE | Sued by NPE |
|-----------------------|----------------------|------------------------|-----------------------|--------------------------|-----------------------|-------------|
| | Thicket Industries | Non-Thicket Industries | Excluding IT Firms | Alternative Cash Measure | All Industries | |
| Cash Level | 0.0891** (0.0353) | 0.0515*** (0.0143) | 0.0543*** (0.0137) | 0.0324*** (0.0124) | 0.0613** (0.0291) | |
| Total Assets | 0.0343 (0.0311) | 0.0192** (0.0085) | 0.0187** (0.0085) | 0.0217** (0.0084) | 0.0209** (0.0092) | |
| Market Value | 0.0014 (0.0180) | -0.0178* (0.0095) | -0.0178** (0.0089) | -0.0126 (0.0083) | -0.0124 (0.0083) | |
| B/M | -0.018 (0.0152) | -0.0147** (0.0067) | -0.0156** (0.0064) | -0.0145** (0.0061) | -0.0149** (0.0061) | |
| Past Return | -0.0017 (0.0052) | -0.0006 (0.0029) | -0.0008 (0.0027) | -0.0002 (0.0025) | -0.0006 (0.0025) | |
| R&D Expense | 0.0578 (0.0867) | 0.1098* (0.0573) | 0.1094** (0.0508) | 0.1362*** (0.0488) | 0.1230** (0.0482) | |
| Number of Patents | 0.0054 (0.0057) | -0.0058 (0.0049) | -0.0037 (0.0041) | 0.0007 (0.0038) | 0.0006 (0.0038) | |
| Cash Shock | 0.0339** (0.0171) | 0.0107 (0.0092) | 0.0211** (0.0088) | 0.0202** (0.0081) | 0.0167** (0.0081) | |
| Financial Constraints | | | | | | |
| Cash Level Squared | | | | | | |
| Cash Level Cubed | | | | | | |
| Firm FE | Yes | Yes | Yes | Yes | Yes | Yes |
| Year FE | Yes | Yes | Yes | Yes | Yes | Yes |
| N | 13,791 | 37,174 | 43,430 | 50,965 | 50,965 | 50,965 |
| R2 | 0.56 | 0.54 | 0.54 | 0.55 | 0.55 | 0.55 |

Panel B. Alternative Estimation Methods

| | Sued by NPE | | Sued by NPE | | Sued by NPE | |
|-------------------|----------------------------|------------------------------|-----------------------|----------------------------|------------------------------|-----------------------|
| | OLS (Number of Times Sued) | Tobit (Number of Times Sued) | Probit (Sued or Not) | OLS (Number of Times Sued) | Tobit (Number of Times Sued) | Probit (Sued or Not) |
| Cash Level | 0.4439*** (0.1638) | 1.9722*** (0.1645) | 0.2896*** (0.0466) | 0.4439*** (0.1638) | 1.9722*** (0.1645) | 0.2896*** (0.0466) |
| Total Assets | 0.2309** (0.0939) | -0.1947* (0.1018) | -0.0113 (0.0315) | 0.2309** (0.0939) | -0.1947* (0.1018) | -0.0113 (0.0315) |
| Market Value | -0.2695** (0.1065) | 2.3869*** (0.1151) | 0.3408*** (0.0364) | -0.2695** (0.1065) | 2.3869*** (0.1151) | 0.3408*** (0.0364) |
| B/M | -0.1620*** (0.0392) | -0.0943 (0.1394) | -0.0385 (0.0393) | -0.1620*** (0.0392) | -0.0943 (0.1394) | -0.0385 (0.0393) |
| Past Return | -0.0147 (0.0146) | -0.1791 (0.1322) | -0.0087 (0.0193) | -0.0147 (0.0146) | -0.1791 (0.1322) | -0.0087 (0.0193) |
| R&D Expense | 5.9518*** (1.8900) | 2.6446*** (0.2524) | 0.1843 (0.1274) | 5.9518*** (1.8900) | 2.6446*** (0.2524) | 0.1843 (0.1274) |
| Number of Patents | 0.1408** (0.0664) | 0.5181*** (0.0350) | 0.0918*** (0.0120) | 0.1408** (0.0664) | 0.5181*** (0.0350) | 0.0918*** (0.0120) |
| Cash Shock | 0.0086 (0.0580) | 0.1677 (0.2272) | 0.0564 (0.0420) | 0.0086 (0.0580) | 0.1677 (0.2272) | 0.0564 (0.0420) |
| Firm FE | Yes | No | No | Yes | No | No |
| Year FE | Yes | Yes | Yes | Yes | Yes | Yes |
| N | 50,965 | 50,965 | 50,965 | 50,965 | 50,965 | 50,965 |
| R2 | 0.75 | 0.14 | 0.20 | 0.75 | 0.14 | 0.20 |

Table IX. Impact of IP Litigation on Real Outcomes

In Panel A of this table, we present the impact of being sued by a NPE, Patent Asserter, or PE on research and development expenditures in the two years following litigation filing, in comparison to the two years before litigation filing. We use the timing of the case filing as the expectations regarding the case outcome start impacting firm operations after the litigation event becomes common knowledge. Following Allison, Lemley, and Walker (2010), we exclude case outcomes such as “Stayed,” “Transfers,” and “procedural dispositions.” We only use case outcomes RPX codes as “Dismissed,” “Settled,” “Won by NPE,” and “Lost by NPE.” In our sample, settlements and won by NPE result in 88 percent of the outcomes, while dismissals and lost by NPE arise in 12 percent of the cases. We compare two groups of firms based on case outcomes of “Settled or Won by NPE” to “Dismissed or Lost by NPE”. In the first row of Panel A, we consider the change in R&D expense, before and after litigation filing, comparing defendant firms whose cases were “Settled or Won by NPE” with those whose cases were “Dismissed or Lost by NPE”. We compare average R&D expense spending two years following the litigation filing to average R&D expense spending two years before the litigation filing. Using this difference-in-differences design, we report mean of Change in R&D (treated) – Change in R&D (untreated). We note that some settlements do not necessarily involve conditions that could be significantly different from dismissals. Furthermore, a given firm may be sued multiple times in a given year and these cases may end with different outcomes. To define the treatment sample cleanly, we assume that a firm can only be grouped into the treated sample if *all* the cases against that firm in a given year conclude with “Settled or Won by NPE” outcomes. These assumptions assure that the effects we document are conservative. In Panel B, Column 3 we test whether the research outputs of the treated and untreated sets were similar prior to litigation, i.e. R&D expense change from year $t - 3$ to $t - 2$. In the first column of Panel C, we report the results of the OLS regression in which future R&D Expense (scaled by total assets) is regressed on a dummy variable that takes a value of 1 if all the cases filed by NPEs against the firm in a particular year are settled or won by the NPE. The unit of observation is firm-year. To measure the future R&D Expense, we use average of R&D spending two years following the litigation. To calculate Citation Commonality, we do the following: First, we count the number patents citing a given patent of a firm and the asserted patent of NPE. We then add up the these figures for all patents of the firm. Standard errors, clustered by firm, are reported in parentheses. ***, **, and * denote statistical significance at the 1, 5, and 10 percent levels.

Panel A. Real Effect Analysis

| Sued by | Treated | Untreated | N(Treated) | N(Untreated) | Change in R&D around litigation |
|-----------------|------------------------------|---------------------------------|------------|--------------|---------------------------------|
| NPE | Settled + Won by NPE | Dismissed + Lost by NPE | 1,929 | 533 | -163.97 (7.18) |
| Patent Asserter | Settled + Won by P. Asserter | Dismissed + Lost by P. Asserter | 1,868 | 502 | -155.02 (6.60) |
| PE | Settled + Won by PE | Dismissed + Lost by PE | 175 | 38 | 167.657 (1.28) |

Panel B. Parallel Trend Analysis

| Sued by | Treated | Untreated | Change in R&D prior to litigation |
|-----------------|------------------------------|---------------------------------|-----------------------------------|
| NPE | Settled + Won by NPE | Dismissed + Lost by NPE | 18.951 (1.18) |
| Patent Asserter | Settled + Won by P. Asserter | Dismissed + Lost by P. Asserter | -1.95 (0.06) |
| PE | Settled + Won by PE | Dismissed + Lost by PE | 50.79 (0.31) |

Panel C. Real Effects OLS Analysis: Settled + Won by NPE vs. Dismissed + Lost by NPE

| Sued by | NPE | Patent Asserter | PE |
|------------------------------|------------------------|------------------------|------------------------|
| | Future R&D/A | Future R&D/A | Future R&D/A |
| Dummy (Settled + Won by NPE) | -0.0173** (0.0081) | -0.0179** (0.0082) | 0.0058 (0.0306) |
| Market Value | -0.0238*** (0.0048) | -0.0230*** (0.0047) | -0.0275** (0.0127) |
| B/M | -0.0468*** (0.0070) | -0.0447*** (0.0068) | -0.1266*** (0.0361) |
| Past Return | -0.0061 (0.0068) | -0.005 (0.0069) | -0.0527 (0.0410) |
| Cash Level | 0.0174*** (0.0056) | 0.0160*** (0.0055) | 0.0138 (0.0222) |
| Cash Shock | 0.0137* (0.0071) | 0.0135* (0.0071) | 0.0162 (0.0277) |
| Citation Commonality | 0.0046*** (0.0008) | 0.0048*** (0.0009) | -0.0005 (0.0011) |
| Ongoing Cases | -0.0513*** (0.0097) | -0.0508*** (0.0096) | -0.0832** (0.0333) |
| Year Fixed Effects | Yes | Yes | Yes |
| N | 2,462 | 2,370 | 209 |
| R2 | 0.13 | 0.13 | 0.15 |

Table X. NPE Litigation and Individual Inventor Patenting Activity, 1995–2015

In this table, we estimate an OLS model using past NPE litigation activity to predict the share of all future patents produced by individual innovators (Individual Innovator Share). The unit of observation is year-IPC subclass code. We exclude patents if a technology class (IPC code) is not reported in the Thompson Innovation database. Individual Innovator patents are those which name the same individual as the “innovator” and “assignee.” If a patent belongs to multiple IPC subclasses, it is counted towards each. We define past litigation activity by calculating the average number of NPE litigation events in the past 3, 4, and 5 years (Litigation3, Litigation4, and Litigation5). Standard errors are clustered by year and reported in parenthesis. ***, **, and * refer to statistical significance at 1, 5 or 10 percent level.

| | Individual Innovator Share | Individual Innovator Share | Individual Innovator Share |
|---------------|----------------------------|----------------------------|----------------------------|
| Litigation5 | -2.0158 (2.5914) | | |
| Litigation4 | | -2.0362 (2.3644) | |
| Litigation3 | | | -2.0699 (2.1816) |
| Tech Group FE | Yes | Yes | Yes |
| Year FE | Yes | Yes | Yes |
| N | 8,975 | 8,975 | 8,975 |
| R2 | 0.80 | 0.80 | 0.80 |

Figure 1. Time Series of NPE, PE, and Total IP Litigation

This figure shows the number of unique dockets in PACER (Public Access to Court Electronic Records) classified as patent cases (PACER code 830) in which at least one of the defendants is a public firm. We use RPX's classification of plaintiffs to split dockets according to whether the plaintiff is an NPE or a PE.





Figure 2. Geography of Patent Assertion

This map shows the geography of patent infringement lawsuits filed by Non-Practicing Entities (NPEs) against publicly traded firms in the United States between 2005 and 2015.



**Appendix – Patent Trolls: Evidence
from Targeted Firms**

Appendix Table A1: Definitions of Variables

| | Definition | Source |
|------------------------------------|---|-------------------------------|
| NPE/PE Litigation | A dummy variable equal to 1 if a firm was litigated by an NPE or a PE in a given year. | RPX |
| NPE Litigation (CKS Sample) | A dummy variable equal to 1 if the firm was litigated by an NPE in 2010 or 2012. | npedata.com |
| R&D Expense | R&D Expense reported on annual income statement. | Compustat |
| Patent Stock | Number of patents issued to the firm in the past five years. We use the final year of the KPSS database (2010) to proxy for the patent stock of companies between 2011 and 2014. | Kogan et al. (2012) |
| IP Legal Team Size | A dummy variable equal to 1 if the firm employs more IP focused law firms than a comparable firm with similar characteristics. See Appendix Table A2 for details. | ALM Legal Intelligence |
| In-house Counsel | A dummy variable equal to 1 if a firm employs an in-house counsel. | ALM Legal Intelligence |
| Ongoing Cases | A dummy variable equal to 1 of if the number of ongoing litigation the firm is engaged is more than 10% of sum of that of its peers in the same industry-year. | Audit Analytics |
| Market Value | Market value of firm equity as of the end of the previous fiscal year. | Compustat |
| Total Assets | Total firm assets as of the end of the previous fiscal year. | Compustat |
| Book to Market | Ratio of firm book value of equity to market value of equity as of the end of the previous fiscal year. (Book value of equity is the sum of stockholders equity (SEQ), Deferred Tax (TXDB), and Investment Tax Credit (ITCB), minus Preferred Stock (PREF). Depending on data availability, we use redemption (item PSTKR) or liquidation (item PSTKL), or par value (item PSTK) to represent the book value of preferred stock. | Compustat |
| Past Return | Stock market return to equity corresponding to the fiscal year. | CRSP |
| Cash Level | The firm's level of cash at the end of the previous fiscal year. | Compustat |
| Cash Shock | A dummy variable that takes a value of 1 if change in cash in the past fiscal year is among the top 5% of cash changes in its industry. | Compustat |
| Citation Commonality | To construct this, we use the Ambercite data, which provides the pairwise similarity between any two patents as the number of patents citing the patent pair together. We aggregate this to the portfolio level of patents for each firm, and compare it to any given patent that is asserted against the firm. | Ambercite.com |

Appendix Table A2: Measuring Legal Team Size

In this table, we measure firms' IP legal team sizes, using a model that predicts the number of IP law firms used by comparable firms. We obtain list of all law firms and their client lists from ALM Legal Intelligence (from 2005–2012). For each law firm reported in the ALM database, we collect two pieces of information from firm websites: (a) whether the law firm has an IP litigation practice, and (b) how important the law firm's IP practice is within the law firm. We calculate each firm's IP legal team size variable after incorporating this additional information. Specifically, we regress log number of (one plus) IP law firms representing the firm in a given year on total assets of the firm, an indicator variable representing the existence of in-house counsel, log number of (one plus) law firms representing the firm in all non IP cases, and firm fixed effects. We use the residual of this estimation to measure of IP Legal Team Size for each firm-year (IP Legal Team Size=1 when residuals>0.) To accommodate the possibility that a given firm may choose not to report representation by law firms in a particular year, we impute the missing observations by using the representation information in the most immediate previous year (our results are not sensitive to this imputation method).

| | Number of IP Law Firms |
|------------------|------------------------|------------------------|------------------------|------------------------|
| Other Law Firm | 0.8173*** (0.0080) | | | 0.8212*** (0.0082) |
| Total Assets | | 0.2290*** (0.0241) | | -0.0206*** (0.0085) |
| In-house Counsel | | | 0.6702*** (0.0601) | -0.026 (0.0261) |
| Firm FE | Yes | Yes | Yes | Yes |
| N | 37,947 | 37,947 | 37,947 | 37,947 |
| R2 | 0.95 | 0.7 | 0.71 | 0.95 |

Appendix Table A4: NPE Categories and Analysis Using Alternative Sample from Cotropia, Kesan, and Schwartz (2014)

In Panel A of this appendix, we utilize a second sample, constructed by Cotropia, Kesan, and Schwartz (2014) and provided on npe-data.com (CKS). CKS hand-coded all patent-holder litigants from the years 2010 and 2012, and classified the nature of the litigants. CKS broke down the litigants into several categories of NPEs (such as “large aggregators” and “patent holding companies”). To accommodate comparability across databases, we matched plaintiff types into three broad categories: (1) Patent Asserter, (2) Small Inventor, and (3) Other. We report the percentages of litigation by category, as a percentage of total cases with NPE plaintiffs. In tabulating the CKS database, we separated out 3,950 observations that are classified as PEs (labeled as “operating companies” by CKS). These cases are used to replicate our PE vs. PE analysis. In first column of Panel B, we conduct the same analysis as in Table II, for 2010 and 2012 using RPX data. In columns 2-5, we replicate our Table V using the CKS data. Because the CKS data cover only two years (2010 and 2012), we cannot include firm fixed effects in the specification; however, we do include 4-digit SIC code fixed effects to capture industry-specific variation. In the last column of Panel B, we report the baseline result after excluding IT firms (SIC Code 35 (e.g., Apple and IBM) and SIC Code 73 (e.g., Yahoo and Ebay)). In Panel C, we perform a similar analysis for PE vs. PE cases. In column 1, we use RPX data for years 2010 and 2012. In Column 2, we define Sued by PE to be equal to 1 if a firm faces IP lawsuits from practicing entities (PEs) in a given year, as defined in CKS sample. In Column 3, we exclude pharmaceutical industries from the sample. Standard errors, clustered by firm, are reported in parentheses. ***, **, and * denote statistical significance at the 1, 5, and 10 percent levels.

Panel A. NPE Classification Comparison

| RPX Database (2005-2015) | | CKS Database (2010 and 2012) | |
|----------------------------------|--------|------------------------------|-------------------------------------|
| Patent Asserter | 87.98% | 62.43% | Patent holding company |
| | | 10.13% | Large aggregator |
| Small Inventor | 9.63% | 15.67% | Individual/family trust |
| | | 1.31% | IP Holding company of operating |
| | | 3.22% | Technology development company |
| NCE | 1.31% | 5.70% | Failed operating company/failed st. |
| University/ Research Institute | 1.07% | 1.55% | University/College |
| Number of cases (docket x court) | 21,300 | 3,753 | Number of cases (docket x court) |

Panel B. Analysis using Data from Cotropia, Kesan and Schwartz (2014): NPE vs. PE cases

| | RPX | | CKS | | CKS | | CKS | | CKS | |
|-------------------|-----------------------|------------------------|------------------------|-------------------------|------------------------|----------------------------|-----------------------|-----------------------|-----------------------|------------------------|
| | Sued by NPE | Sued by NPE | Sued by NPE | Sued by Patent Asserter | Sued by Small Inventor | Sued by NPE (excluding IT) | Sued by NPE | Sued by NPE | Sued by NPE | Sued by NPE |
| Cash Level | 0.0332* (0.0199) | 0.0360** (0.0170) | 0.0401*** (0.0126) | 0.0038 (0.0102) | 0.0384** (0.0158) | 0.0038 (0.0102) | 0.0038 (0.0102) | 0.0038 (0.0102) | 0.0038 (0.0102) | 0.0038 (0.0102) |
| Total Assets | 0.0321*** (0.0118) | -0.0051 (0.0074) | -0.0072 (0.0074) | 0.0039 (0.0035) | 0.0043 (0.0071) | 0.0039 (0.0035) | 0.0039 (0.0035) | 0.0039 (0.0035) | 0.0039 (0.0035) | 0.0043 (0.0071) |
| Market Value | 0.0702*** (0.0166) | 0.0354*** (0.0113) | 0.0284** (0.0113) | 0.0181*** (0.0055) | 0.0234** (0.0107) | 0.0354*** (0.0113) | 0.0354*** (0.0113) | 0.0354*** (0.0113) | 0.0354*** (0.0113) | 0.0234** (0.0107) |
| B/M | -0.0245* (0.0125) | -0.0177*** (0.0064) | -0.0172*** (0.0064) | -0.0015 (0.0031) | -0.0207*** (0.0070) | -0.0245* (0.0125) | -0.0245* (0.0125) | -0.0245* (0.0125) | -0.0245* (0.0125) | -0.0207*** (0.0070) |
| Past Return | -0.0101* (0.0052) | -0.0064* (0.0035) | -0.0058 (0.0035) | -0.0021 (0.0017) | -0.0072* (0.0040) | -0.0101* (0.0052) | -0.0101* (0.0052) | -0.0101* (0.0052) | -0.0101* (0.0052) | -0.0072* (0.0040) |
| R&D Expense | 0.1511*** (0.0529) | 0.1061 (0.0674) | 0.1122* (0.0677) | 0.0566** (0.0247) | -0.003 (0.0525) | 0.1511*** (0.0529) | 0.1511*** (0.0529) | 0.1511*** (0.0529) | 0.1511*** (0.0529) | -0.003 (0.0525) |
| Number of Patents | 0.0175*** (0.0039) | 0.0125*** (0.0041) | 0.0084** (0.0033) | 0.0044** (0.0019) | 0.0062 (0.0045) | 0.0175*** (0.0039) | 0.0175*** (0.0039) | 0.0175*** (0.0039) | 0.0175*** (0.0039) | 0.0062 (0.0045) |
| Cash Shock | 0.0081 (0.0205) | 0.0101 (0.0173) | 0.0105 (0.0166) | 0.0087 (0.0112) | 0.0016 (0.0174) | 0.0081 (0.0205) | 0.0081 (0.0205) | 0.0081 (0.0205) | 0.0081 (0.0205) | 0.0016 (0.0174) |
| Industry FE | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| Year FE | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
| N | 8,746 | 8,746 | 8,746 | 8,746 | 8,746 | 8,746 | 8,746 | 8,746 | 8,746 | 6,406 |
| R2 | 0.35 | 0.17 | 0.16 | 0.13 | 0.17 | 0.13 | 0.13 | 0.13 | 0.13 | 0.17 |

Panel C. Analysis using Data from Cotropia, Kesan and Schwartz (2014): PE vs. PE cases

| | RPX | | CKS | | CKS | |
|-------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|-----------------------|
| | Sued by PE |
| | | | | | (Excluding Pharma.) | |
| Cash Level | -0.0125 (0.0177) | 0.0165 (0.0161) | 0.0209 (0.0157) | -0.0117* (0.0069) | 0.0381*** (0.0103) | 0.0209 (0.0157) |
| Total Assets | 0.0005 (0.0086) | -0.0094 (0.0070) | 0.0405*** (0.0105) | 0.0405*** (0.0105) | 0.0405*** (0.0105) | -0.0117* (0.0069) |
| Market Value | 0.0493*** (0.0108) | 0.0405*** (0.0105) | 0.0405*** (0.0105) | 0.0405*** (0.0105) | 0.0405*** (0.0105) | 0.0381*** (0.0103) |
| B/M | -0.0009 (0.0067) | -0.0061 (0.0049) | -0.0061 (0.0049) | -0.0061 (0.0049) | -0.0061 (0.0049) | -0.0074 (0.0050) |
| Past Return | -0.0036 (0.0030) | 0 (0.0037) | 0 (0.0037) | 0 (0.0037) | 0 (0.0037) | -0.0001 (0.0041) |
| R&D Expense | 0.1591*** (0.0414) | 0.1177*** (0.0343) | 0.1177*** (0.0343) | 0.1177*** (0.0343) | 0.1177*** (0.0343) | 0.1404*** (0.0454) |
| Number of Patents | 0.0106*** (0.0032) | 0.0140*** (0.0027) | 0.0140*** (0.0027) | 0.0140*** (0.0027) | 0.0140*** (0.0027) | 0.0149*** (0.0030) |
| Cash Shock | 0.0076 (0.0177) | 0.0243 (0.0157) | 0.0243 (0.0157) | 0.0243 (0.0157) | 0.0243 (0.0157) | 0.0317** (0.0150) |
| Industry FE | Yes | Yes | Yes | Yes | Yes | Yes |
| Year FE | Yes | Yes | Yes | Yes | Yes | Yes |
| N | 8,746 | 8,746 | 8,746 | 8,746 | 8,746 | 8,209 |
| R2 | 0.23 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 |

Appendix Table A5. PACER Nature of Suit Codes

This appendix lists the lawsuit codes and their descriptions as classified by PACER (<https://www.PACER.gov/documents/natsuit.pdf>).

| Suit Type | PACER Suit Code | Nature of Suit |
|-------------|-----------------------------------|--|
| TORT | 310 | Airplane |
| | 315 | Airplane Product Liability |
| | 320 | Assault, Libel, & Slander |
| | 330 | Federal Employers's Liability |
| | 340 | Marine |
| | 345 | Marine Product Liability |
| | 350 | Motor Vehicle |
| | 355 | Motor Vehicle Product Liability |
| | 360 | Other Personal Injury |
| | 362 | Personal Injury- Medical Malpractice |
| | 365 | Personal Injury- Product Liability |
| | 367 | Personal Injury - Health Care |
| | 368 | Asbestos Personal Injury Product Liability |
| | 375 | False Claims Act |
| | 370 | Other Fraud |
| | 371 | Truth in Lending |
| | 380 | Other Personal Property Damage |
| 385 | Property Damage Product Liability | |
| CONTRACT | 110 | Insurance |
| | 120 | Marine |
| | 130 | Miller Act |
| | 140 | Negotiable Instrument |
| | 150 | Recovery of Overpayment & Enforcement of Judgment |
| | 151 | Medicare Act |
| | 152 | Recovery of Defaulted Student Loans (Excl. Veterans) |
| | 153 | Recovery of Overpayment of Veteran's Benefit |
| | 160 | Stockholders's Suit |
| | 190 | Other Contract |
| | 195 | Contract Product Liability |
| 196 | Franchise | |
| LABOR | 710 | Fair Labor Standards Act |
| | 720 | Labor/Management Relations |
| | 730 | Labor/Management Reporting & Disclosure Act |
| | 740 | Railway Labor Act |
| | 751 | Family and Medical Leave Act |
| | 790 | Other Labor Litigation |
| | 791 | Employee Retirement Income Security Act |
| SECURITIES | 850 | Securities/Commodities/Exchange |
| ENVIRONMENT | 893 | Environmental Matters |

Appendix Table A6: PE vs. PE case coding

This appendix reports the criteria used to code case outcome variables for the PE vs. PE sample. We find docket numbers of PE vs. PE cases in Lex Machina and record “Patent Case Resolution.” We then read the judgment to identify the nature of dismissal or the party that judgment favored. In cases where the judgment refers to stipulated dismissal, we code the outcome as “settlement.” In Panel B, we report the distribution of PE vs. PE cases based on outcome.

| Coded as | Criteria |
|------------------|--|
| Settlement | Likely Settlement: Stipulated Dismissal |
| Won by Plaintiff | Judgment: Consent Judgment : Claimant Win |
| Won by Defendant | Judgment: Consent Judgment : Claim Defendant Win |
| Dismissed | Judgement: Trial : Dismissed with prejudice |
| Dismissed | Judgement: Trial : Dismissed w/o prejudice |
| Not included | Stayed, Transfers or procedural dispositions |

| | PE vs. PE (%) | NPE vs. PE (%) |
|-------------------|---------------|----------------|
| Dismissed | 5.99 | 6.49 |
| Lost by Plaintiff | 9.53 | 5.68 |
| Settled | 72.73 | 87.39 |
| Won by Plaintiff | 11.75 | 0.45 |
| Total dockets | 451 | 6,042 |